<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 8.0.0.0 [11/14/2016 10:18:06 AM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:sngx="http://www.soligenix.com/20160930"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2016-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
 xmlns:us-types="http://fasb.org/us-types/2016-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="sngx-20160930.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_Custom_01_Feb_2007T00_00_00_TO_28_Feb_2007T00_00_00_LeaseArrangementTypeAxis_DoctorSchaberMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sngx:DoctorSchaberMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-02-01
</xbrli:startDate>
<xbrli:endDate>
2007-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2007T00_00_00_TO_30_Sep_2007T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2007-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-06-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-06-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-06-01
</xbrli:startDate>
<xbrli:endDate>
2013-06-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:LincolnParkCapitaLfundLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-11-01
</xbrli:startDate>
<xbrli:endDate>
2013-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_PlanNameAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_22_Jan_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-03-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2014T00_00_00_TO_30_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-04-01
</xbrli:startDate>
<xbrli:endDate>
2014-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-01
</xbrli:startDate>
<xbrli:endDate>
2014-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2014T00_00_00_TO_31_Jul_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2014T00_00_00_TO_19_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-08-01
</xbrli:startDate>
<xbrli:endDate>
2014-08-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-08-01
</xbrli:startDate>
<xbrli:endDate>
2014-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_03_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-03
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_03_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-03
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PlanNameAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">sngx:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PlanNameAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2015T00_00_00_TO_28_Feb_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-02-01
</xbrli:startDate>
<xbrli:endDate>
2015-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KodiakMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:KodiakMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KingsbrookMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:KingsbrookMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_RiverNorthMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:RiverNorthMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">sngx:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">sngx:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-09-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-01
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">sngx:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sngx:ExercisedWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sngx:ExercisedWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sngx:ExercisedWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeFiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_ShareBasedCompensationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:ShareBasedCompensationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeTaxAuthorityNameAxis_NewJerseyDivisionOfTaxationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_EquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sngx:EquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sngx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sngx:ExercisedWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sngx:ExercisedWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sngx:ExercisedWarrantsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeFiveMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sngx:RangeFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeTaxAuthorityNameAxis_NewJerseyDivisionOfTaxationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_EmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">sngx:EmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_22_Mar_2016T00_00_00_TO_22_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:LincolnParkCapitaLfundLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-03-22
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Mar_2016T00_00_00_TO_22_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:LincolnParkCapitaLfundLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-21
</xbrli:startDate>
<xbrli:endDate>
2016-03-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_May_2016T00_00_00_TO_31_May_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-05-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-05-01
</xbrli:startDate>
<xbrli:endDate>
2016-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_29_Aug_2016T00_00_00_TO_29_Aug_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-08-29
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2016T00_00_00_TO_29_Aug_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-08-01
</xbrli:startDate>
<xbrli:endDate>
2016-08-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">sngx:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:LincolnParkCapitaLfundLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">sngx:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KodiakMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:KodiakMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KingsbrookMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:KingsbrookMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_RiverNorthMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sngx:RiverNorthMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_StatementScenarioAxis_DirectorsUponReElectionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">sngx:DirectorsUponReElectionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_StatementScenarioAxis_PermanentEmployeesOrDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">sngx:PermanentEmployeesOrDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_StatementScenarioAxis_TerminatedEmployeesOrDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">sngx:TerminatedEmployeesOrDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_NovemberTwoThousandSixteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">sngx:NovemberTwoThousandSixteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_MarchTwoThousandNineteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">sngx:MarchTwoThousandNineteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:VaccinesBioDefenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sngx:BioTherapeuticsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_NovemberTwoThousandSixteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">sngx:NovemberTwoThousandSixteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_MarchTwoThousandNineteenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">sngx:MarchTwoThousandNineteenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2016T00_00_00_TO_11_Nov_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000812796</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-11-01
</xbrli:startDate>
<xbrli:endDate>
2016-11-11
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw:6c444c555cT{h>G7I<998=1757718EG:1<E:5149<554G54EHG -->
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Segments"><xbrli:measure>sngx:Segments</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">SOLIGENIX, INC.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">0000812796</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentType contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">S-1</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">2016-09-30</dei:DocumentPeriodEndDate>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">5856242</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5525094</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4033326</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">4921545</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5655200</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">794767</us-gaap:GrantsReceivableCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1985212</us-gaap:GrantsReceivableCurrent>
<us-gaap:GrantsReceivableCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1697632</us-gaap:GrantsReceivableCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">172928</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">244267</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">225614</us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">6492789</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">7151024</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">7578446</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">51510</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">47366</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">33050</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">409949</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">188732</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">142308</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">6954248</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">1025220</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">204308</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">5724720</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">7387122</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">2123676</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">76183</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">5187263</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">7753804</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">1801149</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">56555</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">5896100</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3003545</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2869392</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3120384</us-gaap:AccountsPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">292719</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3789562</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2434101</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1324909</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">315030</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">298675</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">62245</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">7108137</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">7405431</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5583373</us-gaap:LiabilitiesCurrent>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0" id="Item_1">2394</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0" id="Item_3">3127</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0" id="Item_4">3755</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0" id="Item_5">138890066</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0" id="Item_6">146856143</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0" id="Item_7">151959679</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-139046349</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-146877579</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-149793003</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-1769821</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_8">1963</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_9">130567593</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-132339377</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-153889</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_10">2394</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_11">138890066</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-139046349</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-18309</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_12">3127</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_13">146856143</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-146877579</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2170431</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_14">3755</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_15">151959679</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-149793003</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">6954248</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">7387122</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">7753804</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">350000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">350000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">350000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">2393657</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">3126952</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">3754224</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">2393657</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">3126952</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">3754224</us-gaap:CommonStockSharesOutstanding>
<us-gaap:ContractsRevenue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5545468</us-gaap:ContractsRevenue>
<us-gaap:ContractsRevenue contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3874199</us-gaap:ContractsRevenue>
<us-gaap:ContractsRevenue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">5668746</us-gaap:ContractsRevenue>
<us-gaap:ContractsRevenue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">8641348</us-gaap:ContractsRevenue>
<us-gaap:ContractsRevenue contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2959254</us-gaap:ContractsRevenue>
<us-gaap:ContractsRevenue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">8750291</us-gaap:ContractsRevenue>
<us-gaap:RevenueFromGrants contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1497548</us-gaap:RevenueFromGrants>
<us-gaap:RevenueFromGrants contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">5476</us-gaap:RevenueFromGrants>
<us-gaap:RevenueFromGrants contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">127042</us-gaap:RevenueFromGrants>
<us-gaap:RevenueFromGrants contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">127042</us-gaap:RevenueFromGrants>
<us-gaap:RevenueFromGrants contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:RevenueFromGrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">7043016</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">6756388</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">286628</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3879675</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">3879675</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:Revenues contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">5795788</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">5781816</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">13972</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">8768390</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">8754418</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">13972</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2959254</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">2959254</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:Revenues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">8750291</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">8750291</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:CostOfRevenue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5313855</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3050814</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4394915</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">6882204</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2630046</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">7204920</us-gaap:CostOfRevenue>
<us-gaap:GrossProfit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1729161</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">828861</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1400873</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1886186</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">329208</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1545371</us-gaap:GrossProfit>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5086535</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1259015</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3731813</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">5399839</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1177263</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3433595</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">4000000</us-gaap:ResearchAndDevelopmentInProcess>
<us-gaap:ResearchAndDevelopmentInProcess contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3403975</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">839512</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2531744</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3596623</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">650762</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2526255</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">12490510</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2098527</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">6263557</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">8996462</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1828025</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5959850</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-10761349</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">807164</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">-7674381</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-3894132</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1269666</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">653415</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">-959065</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-964016</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4862684</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">1040627</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">-3094883</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-2808428</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-7110276</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">1263709</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">-4487988</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-3885997</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1498817</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">239012</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">-908086</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-829743</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-4414479</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">1291123</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">-2822766</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-2882836</us-gaap:OperatingIncomeLoss>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-3436195</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4047742</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">907368</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1201870</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">176293</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1109192</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:OtherIncome contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherIncome contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherIncome contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherIncome contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">390599</us-gaap:OtherIncome>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1310</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-3728</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-2616</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-8017</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1893</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-736</us-gaap:InterestIncomeExpenseNet>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3437505</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">3437505</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4044014</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">4044014</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-909984</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-909984</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-1209887</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-1209887</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-174400</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">-174400</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1499055</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">1499055</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-7323844</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-8320163</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-616872</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-488933</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeTaxAuthorityNameAxis_NewJerseyDivisionOfTaxationMember" unitRef="USD" decimals="0">488933</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-6706972</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_16"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" id="Item_17"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-6706972</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2774348</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-5772668</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-7831230</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_18"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" id="Item_19"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-7831230</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1673217</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2915424</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_20"/>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" id="Item_21"/>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-2915424</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasic contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_22">-3.25</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_23">1.05</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_24">-2.26</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_25">-3.00</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_26">-0.49</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_27">-0.90</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_28">-4.30</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_29">-0.45</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_30">-2.26</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_31">-3.00</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_32">-0.49</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2" id="Item_33">-1.20</us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF" id="Item_34">2063842</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF" id="Item_35">2648240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF" id="Item_36">2553930</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF" id="Item_37">2606577</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF" id="Item_38">3432081</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF" id="Item_39">3245653</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="0" id="Item_40">2358494</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF" id="Item_41">2829058</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF" id="Item_42">2553930</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="0" id="Item_43">2606577</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF" id="Item_44">3432081</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF" id="Item_45">3347837</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_46">1962644</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_47">2393657</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_48">3126952</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_49">3754224</us-gaap:SharesOutstanding>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="USD" decimals="-5">10600000</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">470475</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_50">23</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_51">470452</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1339177</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_52">84</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_53">1339093</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="USD" decimals="0">676510</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1639110</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_54">267</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_55">1638843</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">7694</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Apr_2014T00_00_00_TO_30_Apr_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">7691</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Jul_2014T00_00_00_TO_31_Jul_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">7690</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_56">23075</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">15301</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">7636</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">38425</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">15184</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">7589</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_57">84135</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="shares" decimals="INF">110000</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_58">266830</us-gaap:StockIssuedDuringPeriodSharesOther>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="USD" decimals="0">500000</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2500000</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_59">455</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_60">2499545</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">500000</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreement>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare contextRef="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">60954</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_61">454577</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">393623</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare>
<sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare contextRef="Context_Custom_21_Mar_2016T00_00_00_TO_22_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="shares" decimals="INF">10000</sngx:IssuanceOfCommonStockPursuantToEquityLinePurchaseAgreementShare>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-453162</sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_62"/>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_63">-453162</sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-41381</sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_64"/>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_65">-41381</sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement>
<sngx:StockIssuanceCostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">256040</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_66">12</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_67">256028</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">232212</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_68">16</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_69">232196</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">52500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_70">8</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_71">52492</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_72">12100</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_73">16628</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Aug_2016T00_00_00_TO_29_Aug_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_74">7500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">28078</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_75">4</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_76">28074</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">19250</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_77">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_78">19247</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_79">3667</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">58608</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3667</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_80">3312</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">174643</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3312</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">303694</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<sngx:StockIssuedDuringPeriodWarrantsExercisedValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1117521</sngx:StockIssuedDuringPeriodWarrantsExercisedValue>
<sngx:StockIssuedDuringPeriodWarrantsExercisedValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_81">175</sngx:StockIssuedDuringPeriodWarrantsExercisedValue>
<sngx:StockIssuedDuringPeriodWarrantsExercisedValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_82">1117346</sngx:StockIssuedDuringPeriodWarrantsExercisedValue>
<sngx:StockIssuedDuringPeriodWarrantsExercisedValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<sngx:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_83">174643</sngx:StockIssuedDuringPeriodSharesWarrantsExercised>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1055490</sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_84"/>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_85">1055490</sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2557331</sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_86"/>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_87">2557331</sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering>
<sngx:ReclassificationOfWarrantLiabilityUponPartialExerciseOfWarrantsIssuedInUnitOffering contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<sngx:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToVendors contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">4775</sngx:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToVendors>
<sngx:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToVendors contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_88"/>
<sngx:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToVendors contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_89">4775</sngx:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToVendors>
<sngx:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToVendors contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquityOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">100002</us-gaap:StockholdersEquityOther>
<us-gaap:StockholdersEquityOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_90">4</us-gaap:StockholdersEquityOther>
<us-gaap:StockholdersEquityOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_91">99998</us-gaap:StockholdersEquityOther>
<us-gaap:StockholdersEquityOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquityOtherShares contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4306</us-gaap:StockholdersEquityOtherShares>
<us-gaap:StockholdersEquityOtherShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_92">4307</us-gaap:StockholdersEquityOtherShares>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3750000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_93">185</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_94">3749815</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_95">184911</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_96">14</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrants>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_97">-14</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrants>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">25000</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">336081</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">14300</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_98">14300</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Feb_2015T00_00_00_TO_28_Feb_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">70179</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">48200</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">812</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">35679</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">19871</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">714</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares contextRef="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2500</sngx:IssuanceOfCommonStockFromCashlessExerciseOfWarrantsShares>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">720150</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_99"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_100">720150</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">654481</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_101"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_102">654481</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">453935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" id="Item_103"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_104">453935</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1937894</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_105">189</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_106">1937705</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_107">188653</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">116932</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:OtherOwnershipInterestsOfferingCosts contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">344808</us-gaap:OtherOwnershipInterestsOfferingCosts>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">245787</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">39625</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">199196</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">6966</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">62840</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">10093</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">50673</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">2074</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">184496</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">29820</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">148913</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">5763</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">247458</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">39925</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">199661</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">7872</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">22466</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">10090</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">10313</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">2063</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">67902</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">30150</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">31309</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">6443</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">720150</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">114920</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">193926</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">411304</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">308847</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">411303</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">134924</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">19344</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">29180</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">86400</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">414112</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">63280</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">88615</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">262217</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">654481</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">111960</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">148244</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">394277</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">260204</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">394277</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">117250</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">25164</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">30496</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">61590</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">453935</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_VaccinesBioDefenseMember" unitRef="USD" decimals="0">77393</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_BioTherapeuticsMember" unitRef="USD" decimals="0">96313</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_CorporateMember" unitRef="USD" decimals="0">280229</us-gaap:ShareBasedCompensation>
<sngx:GainOnSettlementLiability contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">0</sngx:GainOnSettlementLiability>
<sngx:GainOnSettlementLiability contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">390599</sngx:GainOnSettlementLiability>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">256040</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">190261</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">232212</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">52500</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<sngx:WarrantsIssuedToVendors contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-4775</sngx:WarrantsIssuedToVendors>
<sngx:WarrantsIssuedToVendors contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-72319</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1069976</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1190445</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-287580</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">37537</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-14770</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">71339</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-18653</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1483255</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1376391</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccruedSalaries contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">81291</us-gaap:IncreaseDecreaseInAccruedSalaries>
<us-gaap:IncreaseDecreaseInAccruedSalaries contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-266942</us-gaap:IncreaseDecreaseInAccruedSalaries>
<us-gaap:IncreaseDecreaseInAccruedSalaries contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-16354</us-gaap:IncreaseDecreaseInAccruedSalaries>
<us-gaap:IncreaseDecreaseInAccruedSalaries contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-236430</us-gaap:IncreaseDecreaseInAccruedSalaries>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">4240243</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1722293</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2444922</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-641489</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-750356</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
<us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-2466729</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4050375</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-5386308</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-3556913</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">50866</us-gaap:PaymentsToAcquireMachineryAndEquipment>
<us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">22098</us-gaap:PaymentsToAcquireMachineryAndEquipment>
<us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">22098</us-gaap:PaymentsToAcquireMachineryAndEquipment>
<us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">7161</us-gaap:PaymentsToAcquireMachineryAndEquipment>
<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">250000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-300866</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-22098</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-22098</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-7161</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">470475</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1615025</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">3839177</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1639110</us-gaap:ProceedsFromIssuanceOfCommonStock>
<sngx:StockIssuanceCostsAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<sngx:StockIssuanceCostsAssociatedWithEquityLinePurchaseAgreement contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">171091</sngx:StockIssuanceCostsAssociatedWithEquityLinePurchaseAgreement>
<sngx:StockIssuanceCostsAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">171091</sngx:StockIssuanceCostsAssociatedWithEquityLinePurchaseAgreement>
<sngx:StockIssuanceCostsAssociatedWithEquityLinePurchaseAgreement contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">41381</sngx:StockIssuanceCostsAssociatedWithEquityLinePurchaseAgreement>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">300000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1136771</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">28078</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1136771</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1937894</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2436447</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2580705</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">4804857</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">4297729</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-331148</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1491768</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-603549</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">733655</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<sngx:AdditionalPaidInCapitalReclassificationOfWarrantLiability contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1055490</sngx:AdditionalPaidInCapitalReclassificationOfWarrantLiability>
<sngx:AdditionalPaidInCapitalReclassificationOfWarrantLiability contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2557331</sngx:AdditionalPaidInCapitalReclassificationOfWarrantLiability>
<sngx:AdditionalPaidInCapitalReclassificationOfWarrantLiability contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2557331</sngx:AdditionalPaidInCapitalReclassificationOfWarrantLiability>
<sngx:AdditionalPaidInCapitalReclassificationOfWarrantLiability contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<sngx:NotesPayableIssuedInConnectionWithEquityPurchaseAgreement contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<sngx:NotesPayableIssuedInConnectionWithEquityPurchaseAgreement contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">282071</sngx:NotesPayableIssuedInConnectionWithEquityPurchaseAgreement>
<sngx:NotesPayableIssuedInConnectionWithEquityPurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">282071</sngx:NotesPayableIssuedInConnectionWithEquityPurchaseAgreement>
<sngx:NotesPayableIssuedInConnectionWithEquityPurchaseAgreement contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">6994</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">7542</us-gaap:IncomeTaxesPaid>
<us-gaap:NatureOfOperations contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 1. Nature of Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Soligenix, Inc. (the &amp;#8220;Company&amp;#8221;) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (&amp;#8220;CTCL&amp;#8221;), proprietary formulations of oral beclomethasone 17,21-dipropionate (&amp;#8220;BDP&amp;#8221;) for the prevention/treatment of gastrointestinal (&amp;#8220;GI&amp;#8221;) disorders characterized by severe inflammation, including pediatric Crohn&amp;#8217;s disease (SGX203) and acute radiation enteritis (SGX201), and it&amp;#8217;s novel innate defense regulator (&amp;#8220;IDR&amp;#8221;) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s Vaccines/BioDefense business segment includes active development programs for RiVax&amp;#8482;, its ricin toxin vaccine candidate, VeloThrax&amp;#8482;, an anthrax vaccine candidate, OrbeShield&lt;sup&gt;&amp;#174;&lt;/sup&gt;, a GI acute radiation syndrome (&amp;#8220;GI ARS&amp;#8221;) therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported by the heat stabilization technology, known as ThermoVax&lt;sup&gt;&amp;#174;&lt;/sup&gt;, under existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases (&amp;#8220;NIAID&amp;#8221;), the Company will attempt to advance the development of RiVax&amp;#8482; to protect against exposure to ricin toxin. The Company plans to use the funds received under the government contracts with the Biomedical Advanced Research and Development Authority (&amp;#8220;BARDA&amp;#8221;) and NIAID to advance the development of OrbeShield&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;for the treatment of GI ARS.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company generates revenues under government grants primarily from the National Institutes of Health (the &amp;#8220;NIH&amp;#8221;) and government contracts from BARDA and NIAID.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the United States Food and Drug Administration (the U.S. &amp;#8220;FDA&amp;#8221;) regulations, litigation, and product liability.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Liquidity&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width:
 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p
 style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;As of December 31, 2015, the Company had cash and cash equivalents of $4,921,545 as compared to $5,525,094 as of December 31, 2014, representing a decrease of $603,549 or 11%. The decrease in cash was primarily due to net cash used in operations of $5,386,308 partially offset by cash provided by financing activities of $4,804,857. As of December 31, 2015, the Company had working capital of $2,179,694, which excludes a non-cash warrant liability of $2,434,101, as compared to working capital of $3,174,214 as of December 31, 2014, representing a decrease of $994,520 or 31%. The decrease in working capital was primarily the result of expenditures to support the completion of the Phase 2 clinical trial of SGX942 and the initiation of the pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL offset by the $4,804,857 in various financing activities.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Based on the Company&amp;#8217;s current rate of cash outflows, cash on hand, proceeds from its government contract and grant programs,&amp;#160;availability of funds from equity lines and proceeds from the state of New Jersey Technology Business Tax Certificate Transfer Program, management believes that its current cash will be sufficient to meet the anticipated cash needs for working capital and capital expenditures for at least the next twelve months.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Management&amp;#8217;s business plan can be outlined as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Complete enrollment and report preliminary results in the pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Initiate a Phase 3 clinical trial of oral BDP, known as SGX203, for the treatment of pediatric Crohn&amp;#8217;s disease;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Continue to collect the long-term follow-up safety data from the SGX942 Phase 2 proof-of-concept study for the treatment of oral mucositis in head and neck cancer patients and publish the findings from this study;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Obtain FDA agreement on a pivotal Phase 2b/3 protocol of SGX942 for the treatment of oral mucositis in head and neck cancer patients;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Continue development of RiVax&amp;#8482; in combination with ThermoVax&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;technology to develop new heat stable vaccines in biodefense and infectious diseases with the potential to collaborate and/or partner with other companies in these areas;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Advance the preclinical and manufacturing
 development of
 OrbeShield&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;as a biodefense medical countermeasure for the treatment of GI ARS;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Continue to apply for and secure additional government funding for each of our BioTherapeutics and Vaccines/BioDefense programs through grants, contracts and/or procurements;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Acquire or in-license new clinical-stage compounds for development; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 12pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Explore other business development and merger/acquisition strategies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s plans with respect to its liquidity management include, but are not limited to the following:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;The Company has up to $43.0 million in active government contract funding still available to support its associated research programs through 2016 and beyond. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;The Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;The Company will pursue Net Operating Loss (&amp;#8220;NOL&amp;#8221;) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program. Based on the receipt of $488,933 in proceeds of the sale of NJ NOL in 2015, the Company expects to participate in the program during 2016 and beyond;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;The Company has an aggregate of $20.2 million available from equity facilities through 2019; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 12pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;The Company may seek additional capital in the private and/or public equity markets, pursue government contracts and grants as well as business development activities to continue its operations, respond to competitive pressures, develop new products and services, and to support new strategic partnerships. The Company is currently evaluating additional equity financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0pt 0px 12pt 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Reverse Stock Split&lt;/u&gt;&amp;#160;&lt;/p&gt;&lt;p
 style="font: 10pt/normal
 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On October 7, 2016, the Company completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-ten, whereby, once effective, every ten shares of its common stock was exchanged for one share of its common stock. The Company&amp;#8217;s common stock began trading on the OTCQB on a reverse split basis at the market opening on October 7, 2016. All share and per share data have been restated to reflect this reverse stock split.&lt;/p&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
<us-gaap:NatureOfOperations contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;Note 1. Nature of Business&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Basis of Presentation&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Soligenix, Inc. (the &amp;#8220;Company&amp;#8221;) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (&amp;#8220;CTCL&amp;#8221;), proprietary formulations of oral beclomethasone 17, 21-dipropionate (&amp;#8220;BDP&amp;#8221;) for the prevention/treatment of gastrointestinal (&amp;#8220;GI&amp;#8221;) disorders characterized by severe inflammation, including pediatric Crohn&amp;#8217;s disease (SGX203) and acute radiation enteritis (SGX201), and it&amp;#8217;s novel innate defense regulator (&amp;#8220;IDR&amp;#8221;) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s Vaccines/BioDefense business segment includes active development programs for RiVax&amp;#8482;, its ricin toxin vaccine candidate, VeloThrax&amp;#8482;, an anthrax vaccine candidate, OrbeShield&lt;font class="superscript" style="font-size: 6pt; vertical-align: super;"&gt;&amp;#174;&lt;/font&gt;, a GI acute radiation syndrome (&amp;#8220;GI ARS&amp;#8221;) therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported by the heat stabilization technology, known as ThermoVax&lt;font class="superscript" style="font-size: 6pt; vertical-align: super;"&gt;&amp;#174;&lt;/font&gt;, under existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases (&amp;#8220;NIAID&amp;#8221;), the Company will attempt to advance the development of RiVax&amp;#8482; to protect against exposure to ricin toxin. The Company plans to use the funds received under the government contracts with the Biomedical Advanced Research and Development Authority (&amp;#8220;BARDA&amp;#8221;) and NIAID to advance the development of OrbeShield&lt;font class="superscript" style="font-size: 6pt; vertical-align: super;"&gt;&amp;#174;&lt;/font&gt;&amp;#160;for the treatment of GI ARS.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company generates revenues under government grants primarily from the National Institutes of Health (the &amp;#8220;NIH&amp;#8221;) and government contracts from BARDA and NIAID.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the United States Food and Drug Administration (the U.S. &amp;#8220;FDA&amp;#8221;) regulations, litigation, and product liability.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Liquidity&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As of December 31, 2015, the Company had cash and cash equivalents of $4,921,545 as compared to $5,525,094 as of December 31, 2014, representing a decrease of $603,549 or 11%. The decrease in cash was primarily due to net cash used in operations of $5,386,308 partially offset by cash provided by financing activities of $4,804,857. As of December 31, 2015, the Company had working capital of $2,179,694, which excludes a non-cash warrant liability of $2,434,101, as compared to working capital of $3,174,214 as of December 31, 2014, representing a decrease of $994,520 or 31%. The decrease in working capital was primarily the result of expenditures to support the completion of the Phase 2 clinical trial of SGX942 and the initiation of the pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL offset by the $4,804,857 in various financing activities.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Based on the Company&amp;#8217;s current rate of cash outflows, cash on hand, proceeds from its government contract and grant programs, availability of funds from equity lines and proceeds from the state of New Jersey Technology Business Tax Certificate Transfer Program, management believes that its current cash will be sufficient to meet the anticipated
 cash needs for working capital and capital expenditures for at least the next twelve months.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Management&amp;#8217;s business plan can be outlined as follows:&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Complete enrollment and report preliminary results in the pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Initiate a Phase 3 clinical trial of oral BDP, known as SGX203, for the treatment of pediatric Crohn&amp;#8217;s disease;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Continue to collect the long-term follow-up safety data from the SGX942 Phase 2 proof-of-concept study for the treatment of oral mucositis in head and neck cancer patients and publish the findings from this study;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Obtain FDA agreement on a pivotal Phase 2b/3 protocol of SGX942 for the treatment of oral mucositis in head and neck cancer patients;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Continue development of RiVax&amp;#8482; in combination with ThermoVax&lt;font class="superscript" style="font-size: 6pt; vertical-align: super;"&gt;&amp;#174;&lt;/font&gt;&amp;#160;technology to develop new heat stable vaccines in biodefense and infectious diseases with the potential to collaborate and/or partner with other companies in these areas;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Advance the preclinical and manufacturing development of OrbeShield&lt;font class="superscript" style="font-size: 6pt; vertical-align: super;"&gt;&amp;#174;&lt;/font&gt;&amp;#160;as a biodefense medical countermeasure for the treatment of GI ARS;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Continue to apply for and secure additional government funding for each of our BioTherapeutics and Vaccines/BioDefense programs through grants, contracts and/or procurements;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Acquire or in-license new clinical-stage compounds for development; and&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Explore other business development and merger/acquisition strategies.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s plans with respect to its liquidity management include, but are not limited to the following:&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;The Company has up to $43.0 million in active government contract funding still available to support its associated research programs through 2016 and beyond. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies;&lt;/p&gt;
&lt;p class="blm" style="font:
 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;The Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;The Company will pursue Net Operating Loss (&amp;#8220;NOL&amp;#8221;) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program. Based on the receipt of $488,933 in proceeds of the sale of NJ NOL in 2015, the Company expects to participate in the program during 2016 and beyond;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;The Company has an aggregate of $20.2 million available from equity facilities through 2019; and&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;The Company may seek additional capital in the private and/or public equity markets, pursue government contracts and grants as well as business development activities to continue its operations, respond to competitive pressures, develop new products and services, and to support new strategic partnerships. The Company is currently evaluating additional equity financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Reverse Stock Split&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;On October 7, 2016, the Company completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-ten, whereby, once effective, every ten shares of its common stock was exchanged for one share of its common stock. The Company&amp;#8217;s common stock began trading on the OTCQB on a reverse split basis at the market opening on October 7, 2016. All share and per share data have been restated to reflect this reverse stock split.&lt;/p&gt;</us-gaap:NatureOfOperations>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Operating Segments&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: BioTherapeutics and Vaccines/BioDefense.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Contracts and Grants Receivable&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Contracts and grants receivable consist of unbilled amounts due from various grants from the NIH and contracts from BARDA and NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Intangible Assets&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;One of the most significant estimates or judgments that the Company makes is whether to capitalize or expense patent and license costs. The Company makes this judgment based on whether the technology has alternative future uses, as defined in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 730,&amp;#160;&lt;font class="italic0" style="font-style: italic;"&gt;Research and Development&lt;/font&gt;. Based on this consideration, the Company capitalizes payments made to legal firms that are engaged in filing and protecting rights to intellectual property and rights for its current products in both the domestic and international markets. The Company believes that patent rights are one of its most valuable assets. Patents and patent applications are a key component of intellectual property, especially in the early stage of product development, as their purchase and maintenance gives the Company access to key product development rights from Soligenix&amp;#8217;s academic and industry partners. These rights can also be sold or sub-licensed as part of its strategy to partner its products at each stage of development as the intangible assets have alternative future use. The legal costs incurred for these patents consist of work associated with filing new patents designed to protect, preserve and maintain the Company&amp;#8217;s rights, and perhaps extend the lives of the patents. The Company capitalizes such costs and amortizes intangibles on a straight-line basis over their expected useful life &amp;#8211; generally a
 period of 11 to 16 years.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;These intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable or if the underlying program is no longer being pursued. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and carrying value of the related asset or group of assets. No such write downs have occurred during the years ended December 31, 2015 and 2014.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company did not capitalize any patent related costs during the years ended December 31, 2015 or 2014.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Office furniture and equipment and intangible assets are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company did not record any impairment of long-lived assets for the years ended December 31, 2015 or 2014.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;FASB ASC 820 &amp;#8212;&amp;#160;&lt;font class="italic0" style="font-style: italic;"&gt;Fair Value Measurements and Disclosures,&lt;/font&gt;&amp;#160;defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on December 31, 2015. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Level 1 &amp;#8212; Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1;
 font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Level 2 &amp;#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;Level 3 &amp;#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, accounts payable, notes payable and accrued compensation approximate their fair value based on the short-term maturity of these instruments. The Company recognizes all derivative financial instruments as assets or liabilities in the financial statements and measures them at fair value with changes in fair value reflected as current period income or loss unless the derivatives qualify as hedges. As a result, certain warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering were accounted for as derivatives. See Note 5,&amp;#160;&lt;font class="italic0" style="font-style: italic;"&gt;Warrant Liability&lt;/font&gt;.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Revenue Recognition&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s revenues are primarily generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Research and Development Costs&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Research and development costs are charged to expense when incurred in accordance with FASB ASC 730,&lt;font class="italic0" style="font-style: italic;"&gt;Research and Development&lt;/font&gt;. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Purchased in-process research and development expense represents the value assigned or paid for acquired research and development for which there is no alternative future use as of the date of acquisition.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Accounting for Warrants&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considered FASB ASC 815,&amp;#160;&lt;font class="italic0" style="font-style: italic;"&gt;Evaluating Whether an Instrument is Considered Indexed to an Entity&amp;#8217;s Own Stock&lt;/font&gt;, which provides guidance for determining whether an equity-linked financial instrument (or embedded feature) issued by an entity is indexed to the entity&amp;#8217;s stock, and, therefore, qualifying for the first part of the scope exception in paragraph 815-10-15. The Company evaluated the provisions in its outstanding warrants and determined that warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering contains provisions that protect holders from a decline in the issue price of the Company&amp;#8217;s common stock (or &amp;#8220;down-round&amp;#8221; provisions) and contain net settlement
 provisions. Consequently, these warrants are recognized as liabilities at their fair value on the date of grant and remeasured at fair value on each reporting date. All other warrants issued were indexed to the Company&amp;#8217;s stock and therefore are accounted for as equity instruments for 2015 and 2014.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees vest 25% on the grant date, then 25% each subsequent year for a period of three years. Stock options vest over each three-month period from the date of issuance to the end of the three year period. These options have a ten year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed. Typically these instruments vest upon issuance and therefore the entire share-based compensation expense is recognized upon issuance to the vendors and/or consultants.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Share-based compensation expense for options, warrants and shares of common stock granted to non-employees has been determined in accordance with FASB ASC 505-50,&amp;#160;&lt;i&gt;Equity-Based Payments to Non-Employees&lt;/i&gt;, and represents the fair value of the consideration received, or the fair value of the equity instruments issued, whichever may be more reliably measured. For options that vest over future periods, the fair value of options granted to non-employees is amortized as the options vest. The fair value is remeasured each reporting period until performance is complete.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For the year ended December 31, 2015 the Company issued 60,534 stock options at a weighted average exercise price of $11.90 per share. The fair value of options issued during the years ended December 31, 2015 and 2014 was estimated to be $12.20 and $14.80 per share, respectively, using the Black-Scholes option-pricing model and the following assumptions:&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;a dividend yield of 0%;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;an expected life of 4 years;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;volatilities ranging from 121% &amp;#8211; 141% and 128% &amp;#8211; 165% for 2015 and 2014, respectively;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;forfeitures at a rate of 12%; and&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;risk-free interest rates ranging from .98% to 1.53% and 1.05% to 1.43% for 2015 and 2014, respectively.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px;"&gt;The weighted average fair value of each option grant made during 2015 and 2014 was estimated on the date of each grant using the Black-Scholes option pricing model and amortized ratably over the option vesting periods, which approximates the service period.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Income Taxes&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company&amp;#8217;s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2015 and 2014. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at December 31, 2015 and 2014.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Earnings Per Share&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 10pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) excludes dilution and is computed by dividing income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period, as adjusted for the reverse stock split of one-for-ten effective October 7, 2016. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;For the Year Ended&lt;br /&gt;December 31, 2015&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;For the Year Ended&lt;br /&gt;December 31, 2014&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Numerator:&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family:
 minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Net loss for basic earnings per share&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;(7,831,230&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;)&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(6,706,972&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font lang="en-gb"&gt;Less change in fair value of warrant liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;&amp;#8212;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;3,436,195&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font lang="en-gb"&gt;Net loss for diluted earnings per share&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;(7,831,230&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;)&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(10,143,167&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Denominator:&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family:
 minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font lang="en-gb"&gt;Weighted-average basic common shares outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;2,606,577&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,063,842&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font lang="en-gb"&gt;Assumed conversion of dilutive securities:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font
 style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Common stock purchase warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;&amp;#8212;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;294,652&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font lang="en-gb"&gt;Denominator for diluted earnings per share &amp;#8211; adjusted weighted-average&lt;br /&gt;&amp;#160;shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;2,606,577&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,358,494&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td
 width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Basic net loss per share&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;(3.00&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;)&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(3.25&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Diluted net loss per share&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;$&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;(3.00&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;)&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(4.30&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size:
 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb" style="font-family: timesnewromanpsstd-regular; font-weight: normal;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 10pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation because their effect would be anti-dilutive.&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;For the Year Ended December 31, 2015&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;For the Year Ended December 31, 2014&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Common stock purchase warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: #cceeff; padding: 0in; width: 1in;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;492,612&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: #cceeff; padding: 0in; width: 1in;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;254,614&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Stock options&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 1in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;276,861&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 1in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;248,828&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td
 width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 1in; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font class="bold" style="font-weight: bold;"&gt;&lt;font lang="en-gb"&gt;769,473&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 1in; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;503,442&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 10pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Shares issuable upon the exercise of options and warrants outstanding at December 31, 2015 and 2014 were 276,861 and 248,828 shares issuable upon the exercise of options, and 492,612 and 726,950 shares issuable upon the exercise of warrants, respectively. The weighted average exercise price of the Company&amp;#8217;s stock options and warrants outstanding at December 31, 2015 were $21.30 and $7.40 per share, respectively.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Use of Estimates and Assumptions&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions such as the fair value of warrants and stock options and the useful life of intangibles that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2014, FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-15, &amp;#8220;&lt;font class="italic0" style="font-style: italic;"&gt;Presentation of Financial Statements &amp;#8212; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&amp;#8221;&lt;/font&gt;&amp;#160;The amendments in this ASU are intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. Specifically, this ASU provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#8217;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard will have on the Company&amp;#8217;s consolidated financial statements and disclosures.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &amp;#8220;&lt;font class="italic0" style="font-style: italic;"&gt;Leases&lt;/font&gt;&amp;#8221; (topic 842)&lt;font class="italic0" style="font-style: italic;"&gt;.&lt;/font&gt;&amp;#160;The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is evaluating the impact of the adoption of this update on our consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Note 2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Reclassification of Prior Year Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Operating Segments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: BioTherapeutics and Vaccines/BioDefense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Cash and cash equivalents&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times
 new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Contracts and Grants Receivable&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Contracts and grants receivable consist of unbilled amounts due from various grants from the NIH and contracts from BARDA and NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Intangible Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;One of the most significant estimates or judgments that the Company makes is whether to capitalize or expense patent and license costs. The Company makes this judgment based on whether the technology has alternative future uses, as defined in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;. Based on this consideration, the Company capitalizes payments made to legal firms that are engaged in filing and protecting rights to intellectual property and rights for its current products in both the domestic and international markets. The Company believes that patent rights are one of its most valuable assets. Patents and patent applications are a key component of intellectual property, especially in the early stage of product development, as their purchase and maintenance gives the Company access to key product development rights from Soligenix&amp;#8217;s academic and industry partners. These rights can also be sold or sub-licensed as part of its strategy to partner its products at each stage of development as the intangible assets have alternative future use. The legal costs incurred for these patents consist of work associated with filing new patents designed to protect, preserve and maintain the Company&amp;#8217;s rights, and perhaps extend the lives of the patents. The Company capitalizes such costs and amortizes intangibles on a straight-line basis over their expected useful life &amp;#8211; generally a period of 11 to 16 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company did not capitalize any patent related costs during the nine months ended September 30, 2016 and 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;These intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable or if the underlying program is no longer being pursued. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and carrying value of the related asset or group of assets. No such write downs have occurred during the nine months ended September 30, 2016 and 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Office furniture and equipment and intangible assets are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company did not record any impairment of long-lived assets for the nine months ended September 30, 2016 and 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;FASB ASC 820 &amp;#8212;&amp;#160;&lt;i&gt;Fair Value Measurements and Disclosures,&amp;#160;&lt;/i&gt;defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on September 30, 2016. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy
 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 1 &amp;#8212; Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 2 &amp;#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 3 &amp;#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, accounts payable, notes payable and accrued compensation approximate their fair value based on the short-term maturity of these instruments. The Company recognizes all derivative financial instruments as assets or liabilities in the financial statements and measures them at fair value with changes in fair value reflected as current period income or loss unless the derivatives qualify as hedges. As a result, certain warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering were accounted for as derivatives. See Note 5,&amp;#160;&lt;i&gt;Warrant Liability&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color:
 #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company&amp;#8217;s revenues are primarily generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Research and development costs are charged to expense when incurred in accordance with FASB ASC 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Accounting for Warrants&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company considered FASB ASC 815,&amp;#160;&lt;i&gt;Evaluating Whether an Instrument is Considered Indexed to an Entity&amp;#8217;s Own Stock&lt;/i&gt;, which provides guidance for determining whether an equity-linked financial instrument (or embedded feature) issued by an entity is indexed to the entity&amp;#8217;s stock and, therefore, qualifying for the first part of the scope exception in paragraph 815-10-15. The Company evaluated the provisions and determined that warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering contain provisions that protect holders from a decline in the issue price of the Company&amp;#8217;s common stock (or &amp;#8220;down-round&amp;#8221; provisions) and contain net settlement provisions. Consequently, these warrants are recognized as liabilities at their fair value on the date of grant and remeasured at fair value on each reporting date. All other warrants issued were indexed to the Company&amp;#8217;s stock and therefore are accounted for as equity instruments for 2016 and 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing:
 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees vest 25% on the grant date, then 25% each subsequent year for a period of three years. Stock options vest over each three-month period from the date of issuance to the end of the three year period. These options have a ten year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed. Typically these instruments vest upon issuance and therefore the entire share-based compensation expense is recognized upon issuance to the vendors and/or consultants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Share-based compensation expense for options, warrants and shares of common stock granted to non-employees has been determined in accordance with FASB ASC 505-50,&amp;#160;&lt;i&gt;Equity-Based Payments to Non-Employees&lt;/i&gt;, and represents the fair value of the consideration received, or the fair value of the equity instruments issued, whichever may be more reliably measured. For options that vest over future periods, the fair value of options granted to non-employees is amortized as the options vest. The fair value is remeasured each reporting period until performance is complete.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For the nine months ended September 30, 2016 and 2015, the Company issued stock options at a weighted average exercise price of $7.72 and $14.40 per share, respectively. The fair value of options issued during the nine months ended September 30, 2016 and 2015 was estimated using the Black-Scholes option-pricing model and the following assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;a dividend yield of 0%;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;an expected life of 4 years;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal;
 -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;volatility of 116% for 2016 and ranging from 136%-141% for 2015;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;forfeitures at a rate of 12%; and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;risk-free interest rates ranging from 0.96%-1.52% and 0.99%-1.34% for 2016 and 2015, respectively.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The fair value of each option grant made during 2016 and 2015 was estimated on the date of each grant using the Black-Scholes option pricing model and amortized ratably over the option vesting periods, which approximates the service period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company&amp;#8217;s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. No current or deferred income taxes have been provided through September 30, 2016 due to the net operating losses incurred by the Company since its inception. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2016 and 2015. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at September 30, 2016 and December 31, 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size:
 10pt;"&gt;&lt;u&gt;Earnings Per Share&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) excludes dilution and is computed by dividing income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: center; text-decoration: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: center; text-decoration: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Nine Months Ended&lt;br /&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;Numerator:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Net income/(loss) for basic earnings per share&lt;/td&gt;
&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;(1,673,217&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;2,774,348&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-weight: bold;"&gt;(2,915,424&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;(5,772,668&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Less change in fair value of warrant liability&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight:
 bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,047,742&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,109,192&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Net loss for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,673,217&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,273,394&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(4,024,616&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(5,772,668&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;Denominator:&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Weighted-average basic common shares outstanding&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;b&gt;3,432,081&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,648,240&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;b&gt;3,245,653&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,553,930&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Assumed conversion of dilutive securities:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Common stock purchase warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;180,818&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;102,184&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom:
 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Denominator for diluted earnings per share &amp;#8211; adjusted weighted-average shares&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;3,432,081&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,829,058&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;3,347,837&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,553,930&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;Basic net income (loss) per share&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.05&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.90&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(2.26&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;Diluted net loss per share&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.45&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1.20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(2.26&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation because their effect would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform:
 none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left; font-family: 'times new roman', serif;"&gt;Common stock purchase warrants&lt;/td&gt;
&lt;td style="width: 16px; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', serif; font-weight: bold;"&gt;492,614&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', serif;"&gt;188,920&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', serif; font-weight: bold;"&gt;188,920&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', serif;"&gt;492,614&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;Stock options&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;299,752&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;230,074&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;299,752&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;230,074&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;792,366&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;418,994&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;488,672&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;722,686&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The weighted average exercise price of the Company&amp;#8217;s stock options and warrants outstanding at September 30, 2016 were $18.20 and $7.38 per share, respectively, and at September 30, 2015 were $23.30 and $8.00 per share, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Use of Estimates and Assumptions&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions such as the fair value of warrants and stock options and recovery of the useful life of intangibles that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In August 2014, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-15, &amp;#8220;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&amp;#8221; The amendments in this ASU are intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. Specifically, this ASU provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#8217;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard will have on the Company's consolidated financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &amp;#8220;Leases&amp;#8221; (topic 842). The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the update is permitted.&amp;#160;The Company&amp;#160;is evaluating the impact of&amp;#160;the adoption of this update on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, &amp;#8220;Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, and intends to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. It is effective for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption is permitted. The Company is currently evaluating the impact of adoption of this update on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 3. Intangible Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following is a summary of intangible assets which consists of licenses and patents:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Amortization Period (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Net Book Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;" colspan="5"&gt;December 31, 2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 801.67px; padding-left: 10pt;"&gt;Licenses&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: center;"&gt;3.8&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;462,234&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;333,732&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;128,502&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Patents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;1.1&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,893,185&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,832,955&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;60,230&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,355,419&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,166,687&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;188,732&lt;/td&gt;&lt;td style="text-align:
 left;
 padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold;"&gt;December 31, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;Licenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;4.7&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;462,234&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;306,495&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;155,739&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Patents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,893,185&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,638,975&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;254,210&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;2.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,355,419&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,945,470&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;409,949&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Amortization expense was $221,217 and $222,563 in 2015 and 2014, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Based on the balance of licenses and patents at December 31, 2015, the annual amortization expense for each of the succeeding four years is expected to approximate as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Amortization Expense&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1378px; text-align: left;"&gt;2016&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$61,800&lt;/td&gt;&lt;/tr&gt;&lt;tr
 style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$61,800&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$37,300&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2019&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$27,832&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;License fees and royalty payments are expensed annually as incurred, as the Company does not attribute any future benefits of such payments.&lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 3. Intangible Assets&lt;/b&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 10pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The following is a summary of intangible assets which consists of licenses and patents:&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="14%" valign="bottom" style="background: white; padding: 0in; width: 89px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Cost&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="14%" valign="bottom" style="background: white; padding: 0in; width: 87px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Accumulated Amortization&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="14%" valign="bottom" style="background: white; padding: 0in; width: 87px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Net Book&lt;br /&gt;Value&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&lt;u&gt;September 30, 2016&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 8px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 81px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size:
 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Licenses&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 8px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 81px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;462,234&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;354,179&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;108,055&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Patents&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 8px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,893,185&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,858,932&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;34,253&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in;
 width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 8px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,355,419&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,213,111&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;142,308&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&lt;u&gt;December 31, 2015&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 8px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 81px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor;
 border-image: none; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Licenses&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 8px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 81px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;462,234&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;333,732&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;128,502&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Patents&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 8px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,893,185&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,832,955&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height:
 normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;60,230&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 8px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,355,419&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,166,687&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;188,732&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 10pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Amortization expense was $15,589 and $55,929 for the three months ended September 30, 2016 and 2015, respectively, and $46,424 and $165,288 for the nine months ended September 30, 2016 and 2015, respectively.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 10pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Based on the balance of licenses and patents at September 30, 2016, the annual amortization expense for each of the succeeding four years is expected to approximate as follows:&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: white; padding: 0in; width: 500px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="15%" valign="bottom" style="background: white; padding: 0in; width: 90px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Amortization Expense&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: #cceeff; padding: 0in; width: 500px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;October 1 thru December 31, 2016&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%"
 valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;15,376&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: white; padding: 0in; width: 500px;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2017&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;61,800&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: #cceeff; padding: 0in; width: 500px;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2018&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;37,300&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: white; padding: 0in; width: 500px;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2019&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;27,832&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 10pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;License fees and royalty payments are expensed as incurred as the Company does not attribute any future benefits to such payments.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 4. Notes Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On July 29, 2015, the Company entered into equity purchase agreements (the &amp;#8220;Equity Line Purchase Agreements&amp;#8221;) and registration rights agreements with certain accredited institutional investors. Under the Equity Line Purchase Agreements, the investors have agreed to purchase from the Company up to an aggregate of $10 million worth of shares of common stock, from time to time.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In consideration for entering into the Equity Line Purchase Agreements, the Company issued to the investors promissory notes having an aggregate principal amount of $300,000, which were recorded as stock issuance costs. The promissory notes are payable by April 15, 2016, with an issuance date present value of $282,071. The promissory notes did not include terms for interest, therefore the interest was imputed at 9%. Total discount amortization of $10,648 was recorded as interest expense for the year ended December 31, 2015. The discount is being accreted over the term of the promissory notes using the effective interest rate method.&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 4. Notes Payable&lt;/b&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;On July 29, 2015, the Company entered into equity purchase agreements (the &amp;#8220;Equity Line Purchase Agreements&amp;#8221;) and registration rights agreements with certain accredited institutional investors. Under the Equity Line Purchase Agreements, the investors have agreed to purchase from the Company up to an aggregate of $10 million worth of shares of common stock, from time to time.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In consideration for entering into the Equity Line Purchase Agreements, the Company issued to the investors promissory notes having an aggregate principal amount of $300,000, which were recorded as stock issuance costs. The promissory notes were paid on April 15, 2016, and had an issuance date present value of $282,071. The promissory notes did not include terms for interest, therefore the interest was imputed at 9%. Total discount amortization of $7,281 was recorded as interest expense for the nine months ended September 30, 2016. The discount was being accreted over the term of the promissory notes using the effective interest rate method.&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<sngx:WarrantLiabilitiesTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 5. Warrant Liability&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering contain provisions that protect holders from a decline in the issue price of its common stock (or &amp;#8220;down-round&amp;#8221; provision) and contain net settlement provisions. As a result, the Company accounts for these warrants as liabilities instead of equity instruments. Down-round provisions reduce the exercise or conversion price of a warrant if the Company issues equity shares for a price that is lower than the exercise or conversion price of the warrants. Net settlement provisions allow the holder of the warrant to surrender shares underlying the warrant equal to the exercise price as payment of its exercise price, instead of exercising the warrant by paying cash. The Company evaluates whether warrants to acquire its common stock contain provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price and/or shares to be issued under the respective warrant agreements based on a variable that is not an input to the fair value of a &amp;#8220;fixed for fixed&amp;#8221; option. As a result of the Company&amp;#8217;s December 2014 registered public unit offering, the exercise price of warrants outstanding in connection with the public offering completed in June 2013 was adjusted to $6.10 per share. As a result of the Company&amp;#8217;s December 2015 drawdown on the Equity Line Purchase Agreement, the exercise price of warrants outstanding in connection with the public offering completed in June 2013 was adjusted to $5.10 per share.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognized these warrants as liabilities at their fair value on the date of grant and remeasures them to fair value on each reporting date.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognized an initial warrant liability for the warrants issued in connection with the registered public offering completed in June 2013 totaling $4,827,788, which was based on the June 25, 2013 closing price of a share of the Company&amp;#8217;s common stock as reported on OTC Markets of $9.60. During the year ended December 31, 2014, 14,300 shares of common were issued upon 58,608 warrants exercised on a cashless basis. On January 22, 2014, 25,000 warrants were exercised and on August 19, 2014, 33,608 warrants were exercised. The fair value of the warrants exercised in 2014, or $1,055,490 was reclassified from warrant liability to additional paid-in capital on the respective exercise dates. During the year ended December 31, 2015, 168,643 warrants were exercised. The fair value of the warrants exercised in 2015, or $2,557,331 was reclassified from warrant liability to additional paid-in capital on the respective exercise dates. On December 31, 2015, the closing price of the Company&amp;#8217;s common stock as reported on OTC Markets was $11.30. Due to the fluctuations in the market value of the Company&amp;#8217;s common stock from December&amp;#160;31, 2014 through December 31, 2015, the Company recognized a non-cash expense of $1,201,870 for the change in the fair value of the warrant liability for 2015.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The assumptions used in connection with the valuation of warrants issued, using the binomial method, were as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Initial Measurement June 25,&lt;br /&gt;2013&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2013&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercised During 2015&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December 31,&amp;#160;&lt;br /&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 627px; text-align: left;"&gt;Number of shares underlying the warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;541,685&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;530,944&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;472,336&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;168,643&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;303,693&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;16.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;16.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.10&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.10&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.10&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;140&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;135&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;128&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;117-119% &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;98&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.49&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.75&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.38&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;.81-1.06% &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected warrant life (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3.5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;3.01-3.33 &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;
 background-color: #cceeff;"&gt;&lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;9.60&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;18.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;9.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;$ 16.90-$22.20 &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;11.30&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;Recurring Level 3 Activity and Reconciliation&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The table below provides a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3). The table reflects losses for the year ended December 31, 2015 for the financial liability categorized as Level 3 as of December 31, 2015.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3):&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Decrease from Warrants Exercised in 2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Increase in Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; padding-bottom: 1.5pt;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,789,562&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(2,557,331&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,201,870&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,434,101&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sngx:WarrantLiabilitiesTextBlock>
<sngx:WarrantLiabilitiesTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 5. Warrant Liability&lt;/b&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering contain provisions that protect holders from a decline in the issue price of its common stock (or &amp;#8220;down-round&amp;#8221; provision) and contain net settlement provisions. As a result, the Company accounts for these warrants as liabilities instead of equity instruments. Down-round provisions reduce the exercise or conversion price of a warrant if the Company issues equity shares for a price that is lower than the exercise or conversion price of the warrants. Net settlement provisions allow the holder of the warrant to surrender shares underlying the warrant equal to the exercise price as payment of its exercise price,&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;instead of exercising the warrant by paying cash. The Company evaluates whether warrants to acquire its common stock contain provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price and/or shares to be issued under the respective warrant agreements based on a variable that is not an input to the fair value of a &amp;#8220;fixed for fixed&amp;#8221; option. As a result of the Company&amp;#8217;s December 2014 registered public unit offering, the exercise price of warrants outstanding in connection with the public offering completed in June 2013 was adjusted to $6.10 per share. As a result of the Company&amp;#8217;s December 2015 drawings on the Equity Line Purchase Agreements, the exercise price of warrants outstanding in connection with the public offering conducted in June 2013 was adjusted to $5.10 per share. The Company recognized these warrants as liabilities at their fair value on the date of grant and remeasures them to fair value on each reporting date.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company recognized an initial warrant liability for the warrants issued in connection with the registered public offering completed in June 2013 totaling $4,827,788, which was based on the June 25, 2013 closing price of a share of the Company&amp;#8217;s common stock as reported on OTC Markets of $9.60. On September 30, 2016, the closing price of the Company&amp;#8217;s common stock as reported on OTC Markets was $7.70. Due to the fluctuations in the market value of the Company&amp;#8217;s common stock from December 31, 2015 through September 30, 2016, the Company recognized non-cash income of $1,109,192 for the change in the fair value of the warrant liability for the nine months ended September 30, 2016.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 10pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The assumptions used in connection with the valuation of warrants issued utilizing the binomial method were as follows:&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;September 30, 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;December 31, 2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Number of shares underlying the warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in
 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;303,694&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;303,694&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Exercise price&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5.10&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5.10&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Volatility&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;90&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom"
 style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;98&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;0.68&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1.19&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Expected dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;0&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;0&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Expected warrant life (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1.73&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2.48&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Stock Price&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;7.70&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;11.30&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 10pt 0in; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The table below provides a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3). The table reflects gains for the nine months ended September 30, 2016 for the financial liability categorized as Level 3 as of September 30, 2016&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="240" valign="bottom" style="background: white; padding: 0in; width: 2.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height:
 normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;December 31, 2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Decrease from Warrants Exercised in 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Decrease&lt;br /&gt;in Fair Value&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;September 30, 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="240" valign="bottom" style="background: #cceeff; padding: 0in; width: 2.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Warrant liability&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,434,101&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 1in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,109,192&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black;
 line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,324,909&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="240" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="8" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="88" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="96" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="8" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="88" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="8" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="88" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</sngx:WarrantLiabilitiesTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 6. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The income tax benefit consisted of the following for the years ended December 31, 2015 and December 31, 2014:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; padding-bottom: 1.5pt;"&gt;State&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(488,933&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(616,872&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(488,933&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(616,872&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The significant components of the Company&amp;#8217;s deferred tax assets and liabilities at December 31, 2015 and 2014 are as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;31,216,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;29,594,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Orphan drug and research and development credit carry forwards&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,909,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,556,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Equity based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,923,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,049,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Intangibles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,090,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,140,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold;"&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;40,138,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;37,339,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(40,138,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(37,339,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has gross NOLs at December 31, 2015 of approximately $90,891,000 for federal tax purposes and approximately $5,273,000 of New Jersey NOL carry forwards remaining after the sale of unused net operating loss carry forwards, portions of which will begin to expire in 2018. In addition, the Company has $4,909,000 of various tax credits which expire from 2018 to 2034. The Company may be able to utilize its NOLs to reduce future federal and state income tax liabilities. However, these NOLs are subject to various limitations under Internal Revenue Code (&amp;#8220;IRC&amp;#8221;) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownership change of more than 50 percentage points. In addition, the NOL carry forwards are subject to examination by the taxing authority and could be adjusted or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is likely that the utilization of the NOLs may be substantially limited.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company and one or more of its subsidiaries files income tax returns in the U.S. Federal jurisdiction, and various state and local jurisdictions. During the years ended December 31, 2015 and 2014, in accordance with the State of New Jersey&amp;#8217;s Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused net operating loss carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey net operating loss carryforwards, resulting in the recognition of $488,933 and $616,872 of income tax benefit, net of transaction costs, respectively. There can be no assurance as to the continuation or magnitude of this program in the future.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal;
 -webkit-text-stroke-width: 0px;"&gt;Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended December 31, 2015 and 2014 were as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Income tax loss at federal statutory rate&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;(34.00&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;)%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(34.00&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;)%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;State tax benefits, plus sale of NJ NOLs, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(40.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(40.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;34.12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;31.58&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(5.88&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(8.42&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 10pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 6. Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company had gross NOLs at December 31, 2015 of approximately $90,891,000 for federal tax purposes and approximately $5,273,000 of New Jersey NOL carry forwards remaining after the sale of unused net operating loss carry forwards, portions of which will begin to expire in 2018. In addition, the Company has $4,909,000 of various tax credits which expire from 2018 to 2034. The Company may be able to utilize its NOLs to reduce future federal and state income tax liabilities. However, these NOLs are subject to various limitations under Internal Revenue Code (&amp;#8220;IRC&amp;#8221;) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownership change of more than 50 percentage points. In addition, the NOL carry forwards are subject to examination by the taxing authority and could be adjusted or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is likely that the utilization of the NOLs may be substantially limited.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company and one or more of its subsidiaries files income tax returns in the U.S. Federal jurisdiction, and various state and local jurisdictions. During the year ended December 31, 2015, in accordance with the State of New Jersey&amp;#8217;s Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused net operating loss carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey net operating loss carryforwards, resulting in the recognition of $488,933 of income tax benefit, net of transaction costs. There can be no assurance as to the continuation or magnitude of this program in the future.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company has no tax provision for the three and nine month periods ended September 30, 2016 and 2015 due to losses incurred and the recognition of full valuation allowances recorded against net deferred tax assets.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 7. Shareholders&amp;#8217; Deficiency&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has 350,000 shares of preferred stock authorized, none of which are issued or outstanding.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Common Stock&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following items represent transactions in the Company&amp;#8217;s common stock for the year ended December 31, 2015:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In February 2015, the Company issued 70,179 shares of common stock in connection with the exercise of stock warrants;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In March 2015, the Company issued 48,200 shares of common stock in connection with the exercise of stock warrants;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In March 2015, the Company issued 15,301 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In April 2015, the Company issued 35,679 shares of common stock in connection with the exercise of stock warrants;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In April 2015, the Company issued 812 shares of common stock in connection with the exercise of stock options;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In May 2015, the Company issued 7,636 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch:
 normal; -webkit-text-stroke-width: 0px;"
 cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In June 2015, the Company issued 38,425 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In June 2015, the Company issued 19,871 shares of common stock in connection with the exercise of stock warrants;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In July 2015, the Company issued 714 shares of common stock in connection with the exercise of stock warrants;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In September 2015, the Company issued 60,954 shares of common stock pursuant to an Equity Line Purchase Agreement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In September 2015, the Company issued 2,500 shares of common stock in connection with the exercise of stock options;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In October 2015, the Company issued 15,184 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In November 2015, the Company issued 7,589 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In December 2015, the Company issued 393,623 shares of common stock pursuant to an Equity Line Purchase Agreement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 12pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In nine separate transactions, the Company issued 16,628 fully vested shares of common stock as partial consideration for services performed.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0pt 0pt 12pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following items represent transactions in the Company&amp;#8217;s common stock for the year ended December 31, 2014:&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In January 2014, the Company issued 7,788 shares of common stock in connection with the cashless exercise of 25,000 stock warrants;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In March 2014, the Company issued 7,694
 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times
 new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In April 2014, the Company issued 7,691 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In May 2014, the Company issued 4,307 shares of common stock upon the execution of an agreement to evaluate specific oncology technology;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In May 2014, the Company issued 2,917 shares of common stock upon the exercise of vested stock options;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In July 2014, the Company issued 7,690 shares of common stock pursuant to the Lincoln Park facility;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In July 2014, the Company issued 750 shares of common stock upon the exercise of vested stock options;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In August 2014, the Company issued 6,512 shares of common stock with the cashless exercise of 33,608 stock warrants;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In September 2014, the Company issued 184,911 shares of common stock in connection with the Hy BioPharma Acquisition of in process research and development.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 7.5pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In December 2014, the Company issued 188,653 shares of common stock and 116,932 warrants pursuant to a registered direct unit offering of common stock and warrants. The Company received net proceeds of $1,937,894 from this offering.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="font: 10pt/normal 'times new roman', serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 12pt; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="width: 36pt;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;In four separate transactions, the Company issued 12,100 shares of common stock as partial consideration for services performed.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0pt 0pt 12pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Equity Line Purchase Agreement&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On July 29, 2015, the Company entered into the Equity Line Purchase Agreements and a registration rights agreements with accredited institutional investors, Kodiak Capital Group, LLC (&amp;#8220;Kodiak Capital&amp;#8221;), Kingsbrook Opportunities Master Fund LP (&amp;#8220;Kingsbrook&amp;#8221;) and River North Equity, LLC (&amp;#8220;River North&amp;#8221; and, together with Kodiak Capital and Kingsbrook, the &amp;#8220;Investors&amp;#8221;). Under the Equity Line Purchase Agreements, the Investors agreed to purchase from the Company up to
 an aggregate of $10 million worth of shares of common stock, from time to time. In accordance with the registration rights agreements, the Company has filed with the U.S. SEC a
 registration statement to register for resale under the Securities Act of 1933, as amended, the shares of common stock that may be issued to the Investors under the Equity Line Purchase Agreements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;From the date that the SEC declared the registration statement effective, in August 2015, until December 31, 2016, the Company has the right to sell up to $5 million, $4 million and $1 million worth of shares of common stock to Kodiak Capital, Kingsbrook and River North, respectively. The Company will control the timing and amount of future sales, if any, of common stock to the Investors under the Equity Line Purchase Agreements. The purchase price of the shares will be equal to eighty percent (80%) of the lowest daily volume weighted average price of the common stock for any trading day during the five consecutive trading days immediately following the date of the Company&amp;#8217;s notice to the Investors requesting the purchase. There is no minimum amount that the Company may require the Investors to purchase at any one time. The Company may not require the Investors to purchase more than $3 million worth of shares of common stock during any seven day period and may not require any of the Investors to purchase shares of common stock if such purchase would result in such Investor&amp;#8217;s beneficial ownership exceeding 9.99% of the outstanding common stock.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Equity Line Purchase Agreements contain customary representations, warranties, covenants, closing conditions, and indemnification and termination provisions. Each of the Investors has covenanted not to cause or engage in any manner whatsoever any direct or indirect short selling of the common stock.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In consideration for entering into the Equity Line Purchase Agreements, the Company issued to each of the Investors a promissory note having a principal amount equal to 3% of the total amount committed by such Investor. The principal amount due under the promissory notes does not accrue interest and is payable by April 15, 2016 (see Note 4).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Equity Line Purchase Agreements may be terminated by the Company at any time at its discretion without any cost to the Company.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The initial drawdown under the Equity Line Purchase Agreements was $500,000 offset by issuance cost of $453,162, which is included in the Consolidated Statements of Changes in Shareholders&amp;#8217; Deficiency. Issuance costs include professional fees, 3% commitment fee (promissory notes payable by April 15, 2016) and SEC filing fees.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In December 2015, a second drawdown was made, whereby under the Equity Line Purchase Agreements, the Company issued 393,624 shares of common stock receiving proceeds of $2,000,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On March 7, 2016, in accordance with the terms of the Equity Line Purchase Agreements, the Company exercised its right to terminate the Purchase Agreements upon written notice to the Investors. The
 Company did not incur any penalties as a result of this termination.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000;
 text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Equity Line&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In November 2013, the Company entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (&amp;#8220;Lincoln Park&amp;#8221;). The Lincoln Park equity facility allows the Company to require Lincoln Park to purchase up to 7,500 shares (&amp;#8220;Regular Purchase&amp;#8221;) of the Company&amp;#8217;s common stock every two business days, up to an aggregate of $10.6 million over approximately a 36-month period depending on certain conditions, including the quoted market price of the Company&amp;#8217;s common stock on such date. The purchase price for the Regular Purchase shall be equal to the lesser of (i) the lowest sale price of the common shares during the purchase date, or (ii) the average of the three lowest closing sale prices of common shares during the twelve business days prior to the purchase date. Each Regular Purchase shall not exceed $750,000. Furthermore, for each additional purchase by Lincoln Park, additional commitment shares in commensurate amounts up to a total of 12,207 shares will be issued based upon the relative proportion of the aggregate amount of $10.0 million. The Regular Purchase amount may be increased up to 10,000 shares of common stock if the closing price of the common shares is not below $25.00. In addition to the Regular Purchase and provided that the closing price of the common shares is not below $15.00 on the purchase date, the Company in its sole discretion may direct Lincoln Park on each purchase date to purchase on the next stock trading day (&amp;#8220;Accelerate Purchase Date&amp;#8221;) additional shares of Company stock up to the lesser of (i) two times the number of shares purchased following a Regular Purchase or (ii) 30% of the trading volume of shares traded on the Accelerated Purchase Date as a price equal to the lesser of the closing sale price on the Accelerated Purchase Date or 95% of the Accelerated Purchase Date&amp;#8217;s volume weighted average price.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;During the year ended December 31, 2014, in three separate transactions, the Company sold 22,500 shares of common stock and issued 575 commitment shares receiving net proceeds of $470,475. During the year ended December 31, 2015, in nine separate transactions, the Company sold 82,500 shares of common stock and issued 1,635 commitment shares receiving net proceeds of $1,339,177.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 7. Shareholders&amp;#8217; Deficiency&lt;/b&gt;&lt;/p&gt;
&lt;p class="h6" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; text-decoration: underline; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Preferred Stock&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company has 350,000 shares of preferred stock authorized, none of which are issued or outstanding.&lt;/p&gt;
&lt;p class="h6" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; text-decoration: underline; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Common Stock&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;During the nine months ended September 30, 2016, the Company issued the following shares of common stock:&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#8226;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;In several separate transactions the Company issued 266,830 shares of common stock pursuant to the equity line with Lincoln Park Capital Fund, LLC (&amp;#8220;Lincoln Park&amp;#8221;);&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#8226;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;On May 31, 2016, the Company issued 5,000 shares of common stock to a vendor for partial consideration for services performed. The market price of the Company&amp;#8217;s common stock was $7.30 on the date issued and the shares were vested on the date of grant.&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#8226;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;On August 29, 2016, the Company issued 2,500 shares of common stock to a vendor for partial consideration for services performed. The market price of the Company&amp;#8217;s common stock was $6.40 on the date issued and the shares were vested on the date of grant.&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#8226;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;On September 9, 2016, the Company and SciClone entered into an exclusive license agreement (the &amp;#8220;License Agreement&amp;#8221;), pursuant to which the Company granted rights to SciClone to develop, promote, market, distribute and sell SGX942 in the People&amp;#8217;s Republic of China, including Hong Kong and Macau, as well as Taiwan, South Korea and Vietnam (the &amp;#8220;Territory&amp;#8221;). Under the terms of the License Agreement, SciClone will be responsible for all aspects of development, product registration and commercialization in the Territory, having access to data generated by the Company. In exchange for exclusive rights, SciClone will pay to the Company royalties on net sales, and the Company will supply commercial drug product to SciClone on a cost-plus basis, while maintaining worldwide manufacturing rights. The Company also entered into a common stock purchase agreement with SciClone pursuant to which we sold 352,942 shares of our common stock to SciClone for an aggregate price of $3,000,000.&lt;/p&gt;
&lt;p class="h6" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; text-decoration: underline; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Equity Line Facilities&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In March 2016, the Company entered into a common stock purchase agreement with Lincoln Park. The Lincoln Park equity facility allows the Company to require Lincoln Park to purchase up to 10,000 shares (&amp;#8220;Regular Purchase&amp;#8221;) of the Company&amp;#8217;s common stock every two business days, up to an aggregate of $12.0 million over approximately a 36-month period with such amounts increasing as the quoted stock price increases. The Regular Purchase may be increased up to 15,000 shares of common stock if the closing price of the common shares is not below $10.00, up to 20,000 shares of common stock if the closing price of the common shares is not below $15.00 and up to 25,000 shares of common stock if the closing price of the common shares is not below $20.00. The purchase price for the Regular Purchase shall be equal to the lesser of (i) the lowest sale price of the common shares during the purchase date, or (ii) the average of the three lowest closing sale prices of the common shares during the twelve business days prior to&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;the purchase date. Each Regular Purchase shall not exceed $750,000. Furthermore, for each
 purchase by Lincoln Park, additional commitment shares in commensurate amounts up to a total of 50,000 shares will be issued based upon the relative proportion of the aggregate amount of $12.0 million. In addition to the Regular Purchase and provided that the closing price of the common shares is not below $7.50 on the purchase date, the Company in its sole discretion may direct Lincoln Park on each purchase date to purchase on the next stock trading day (Accelerated Purchase Date&amp;#8221;) additional shares of Company stock up to the lesser of (i) three times the number of shares purchased following a Regular Purchase or (ii) 30% of the trading volume of shares traded on the Accelerated Purchase Date at a price equal to the lesser of the closing sale price on the Accelerated Purchase Date or 95% of the Accelerated Purchase Date&amp;#8217;s volume weighted average price.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Upon entering into the agreement, the Company issued 10,000 shares of common stock as consideration for its commitment to purchase shares of our common stock under the purchase agreement. The value of these shares on the date granted was $81,000, which was accounted for as a stock issuance cost.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;During the quarter ended September 30, 2016, the Company sold Lincoln Park 110,000 shares of common stock for an aggregate price of $676,510 and issued 2,819 additional shares of common stock with a value of $17,377 to Lincoln Park as a commitment fee pursuant to the terms of the agreement. The additional shares issued as a commitment fee were accounted for as a stock issuance cost.&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<sngx:StockOptionPlansAndWarrantsToPurchaseCommonstockTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&lt;b&gt;Note 8. Stock Option Plans and Warrants to Purchase Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-indent: 0.5in;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&lt;u&gt;Stock Option Plans&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The Amended and Restated 2005 Equity Incentive Plan was replaced by the 2015 Equity Incentive Plan (&amp;#8220;2015 Plan&amp;#8221;), approved in June 2015, and is divided into four separate equity programs:&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;1)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Discretionary Option Grant Program, under which eligible persons may, at the discretion of the Plan Administrator, be granted options to purchase shares of common stock,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;2)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Salary Investment Option Grant Program, under which eligible employees may elect to have a portion of their base salary invested each year in options to purchase shares of common stock,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;3)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Automatic Option Grant Program, under which eligible nonemployee Board members will automatically receive options at periodic intervals to purchase shares of common stock, and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;4)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Director Fee Option Grant Program, under which non-employee Board members may elect to have all, or any portion, of their annual retainer fee otherwise payable in cash applied to a special option
 grant.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:
 #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The 2005 Equity Incentive Plan (&amp;#8220;2005 Plan&amp;#8221;) also was divided into four separate equity programs:&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;1)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Discretionary Option Grant Program, under which eligible persons may, at the discretion of the Plan Administrator, be issued common stock or granted options to purchase shares of common stock,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;2)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Salary Investment Option Grant Program, under which eligible employees may elect to have a portion of their base salary invested each year in options to purchase shares of common stock,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;3)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Automatic Option Grant Program, under which eligible nonemployee Board members will automatically receive options at periodic intervals to purchase shares of common stock, and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;4)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;the Director Fee Option Grant Program, under which non-employee Board members may elect to have all, or any portion, of their annual retainer fee otherwise payable in cash applied to a special option grant.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;In addition, under the 2005 Plan, the Board may elect to pay certain consultants, directors, and employees in common stock. The 2005 Plan was amended in September 2007 to increase the number of options available under the plan to 100,000, in 2010 to increase the number of shares under the plan to 175,000 and again in 2013 to increase the number shares available under the plan to 300,000. The 2015 Plan was approved in June 2015 with 300,000 shares available under the plan.&lt;/p&gt;&lt;p style="color:
 #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight:
 normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The table below accounts only for transactions occurring as part of the 2015 Plan.&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="6"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; font-weight: bold; text-align: left;"&gt;Shares available for grant at plan approval&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;300,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;(47,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt;"&gt;Shares available for grant at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;252,300&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The total option activity for the amended 2005 Plan and the 2015 Plan for the years ended December 31, 2015 and 2014 was as follows:&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch:
 normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;p
 style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Options Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; font-weight: bold; padding-bottom: 4pt;"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; border-bottom: 4pt double black; text-align: right;"&gt;205,151&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; border-bottom: 4pt double black; text-align: right;"&gt;26.30&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;63,750&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;17.90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(3,667&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.70&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;(16,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;31.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;248,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;24.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;60,534&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;11.90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(3,312&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;(29,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;31.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;Balance at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;276,861&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;21.30&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;As of December 31, 2015, there were 208,220 options exercisable with a weighted average exercise price of $23.30, a weighted average remaining contractual term of 7.28 years and an intrinsic value of $256,347. The intrinsic value of options exercised during the years ended December 31, 2015 and 2014 was $18,181 and $47,241, respectively. As of December 31, 2015, there were 276,861 options outstanding and expected to vest with a weighted average exercise price of $21.30, weighted average remaining term of 7.28 years and an intrinsic value of $257,369. The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference
 between the closing price of our common stock on the last trading day on December 31, 2015 and the exercise price, multiplied by the number of in-the-money options) what would have been received by the option holders had all option holders exercised their
 options on December 31, 2015. This amount changes based on the fair market value of our common stock.&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The Company awarded 60,534 and 63,750 stock options&amp;#160;to new employees and existing Board members during the years ended 2015 and 2014, respectively. During the year ended 2015, under the 2005 Equity Incentive Plan, 2,900 option grants were issued to employees and 9,934 option grants were issued to Board members, and under the 2015 Equity Incentive Plan 47,700 option grants were issued to employees.&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The weighted-average exercise price, by price range, for outstanding options to purchase common stock at December 31, 2015 was:&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Weighted Average Remaining&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Contractual Life in Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: center;"&gt;$3.00-$22.00&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;8.03&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;217,084&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;148,443&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center;"&gt;$22.60-$41.00&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.36&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;17,477&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;17,477&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:
 bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;$46.40-$94.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;3.22&lt;/td&gt;&lt;td
 style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;42,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;42,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;7.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;276,861&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;208,220&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The Company&amp;#8217;s share-based compensation expense for the years ended December 31, 2015 and 2014 was recognized as follows:&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; font-style: italic; border-bottom: 1.5pt solid black;"&gt;Share-based Compensation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Research and Development&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;260,204&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;308,847&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;General and Administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;394,277&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;411,303&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;654,481&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;720,150&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;
 -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;At December 31, 2015, the total compensation cost for stock options not yet recognized was approximately $773,197 and will be expensed over the next three years.&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal;
 font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px;"&gt;&lt;u&gt;Warrants to Purchase Common Stock&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;Warrant activity for the years ended December 31, 2015 and 2014 was as follows:&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Warrant Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; font-weight: bold;"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;815,653&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;21.70&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;116,932&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(58,608&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;16.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;(147,027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;34.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold;"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;726,950&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(174,643&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.40&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;(59,695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black;
 text-align: right;"&gt;55.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;Balance at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;492,612&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;7.40&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The weighted-average remaining life, by price range, for outstanding warrants at December 31, 2015 was:&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Price&lt;/b&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;Exercisable Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: center;"&gt;$5.10-$5.30&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;2.4&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;381,180&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;381,180&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;$14.80-$20.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;4.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;111,432&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;111,432&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;2.7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;492,612&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;492,612&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sngx:StockOptionPlansAndWarrantsToPurchaseCommonstockTextBlock>
<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 9. Concentrations&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;At December 31, 2015 and 2014, the Company had deposits in major financial institutions that exceeded the amount under protection by the Securities Investor Protection Corporation (&amp;#8220;SIPC&amp;#8221;). Currently, the Company is covered up to $1,000,000 by the SIPC and at times maintains cash balances in excess of the SIPC coverage.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; font-stretch: normal;"&gt;&lt;b&gt;Note 10. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-indent: 0.5in; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; font-stretch: normal;"&gt;The Company has commitments of approximately $500,000 at December 31, 2015 for several licensing agreements with consultants and universities. Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may require the payment of milestones of up to $7.9 million and/or royalties up to 6% of net sales of covered products, if and when achieved. However, there can be no assurance that clinical or commercialization success will occur. As of December 31, 2015 no milestones or royalty payments have been paid or accrued.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; font-stretch: normal;"&gt;In December 2014, the Company entered into a lease agreement through May 31, 2018 for existing and expanded office space. The rent for the first 12 months was approximately $12,300 per month, or approximately $20.85 per square foot. This rent increased to approximately $12,375 per month, or approximately $20.95 per square foot, for the next 12 months and will increase to approximately $12,460 per month, or approximately $21.13 per square foot for the remainder of the lease. The Company paid rent expense in the amount of $142,935 and $94,400 for 2015 and 2014, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; font-stretch: normal;"&gt;On September 3, 2014, the Company entered into an asset purchase agreement with Hy Biopharma, Inc. (&amp;#8220;Hy Biopharma&amp;#8221;) pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma&amp;#8217;s synthetic hypericin product. As consideration for the assets acquired, the Company paid $275,000 in cash and issued 184,911 shares of common stock with a fair value based on the Company&amp;#8217;s stock price on the date of grant of $3,750,000. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in the Company&amp;#8217;s research and development activities and do not have alternative future use pursuant to generally accepted accounting principles in the United States. Provided all future success-oriented milestones are attained, the Company will be required to make additional payments of up to $10.0 million, if and when achieved. Payments will be payable in restricted securities of the Company provided that Hy BioPharma&amp;#8217;s ownership is not to exceed 19.9% of the Company&amp;#8217;s outstanding stock. As of December 31, 2015, no milestone payments have been paid or accrued.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; font-stretch: normal;"&gt;In February 2007, the Company&amp;#8217;s Board of Directors authorized the issuance of 5,000 shares of the Company&amp;#8217;s common stock to Dr. Schaber immediately prior to the completion of a transaction, or series or a combination of related transactions, negotiated by its Board of Directors whereby, directly or indirectly, a majority of its capital stock or a majority of its assets are transferred from the Company and/or its stockholders to a third party. Dr. Schaber&amp;#8217;s amended employment agreement includes the Company&amp;#8217;s obligation to issue such shares if such event occurs.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; font-stretch: normal;"&gt;As a result of the above agreements, the Company has future contractual obligations over the next five years as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in; font-stretch: normal;"&gt;&lt;/p&gt;&lt;br class="apple-interchange-newline" /&gt;2017
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Property and Other Leases&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left;"&gt;2016&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;100,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;157,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;257,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:
 bottom; background-color:
 white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;151,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;251,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;52,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;152,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;2019&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Total&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;500,000&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;360,000&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;860,000&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 12pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 8. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company has commitments of approximately $416,667 as of September 30, 2016 for several licensing agreements with consultants and universities. Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may require the payment of milestones of up to $7.9 million and/or royalties up to 6% of net sales of covered products, if and when achieved. However, there can be no assurance that clinical or commercialization success will occur. As of September 30, 2016, no milestone or royalty payments have been paid or accrued.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In December 2014, the Company entered into a lease agreement through May 31, 2018 for existing and expanded office space. The rent for the first 12 months is approximately $12,300 per month, or approximately $20.85 per square foot. This rent increases to approximately $12,375 per month, or approximately $20.95 per square foot, for the next 12 months and approximately $12,460 per month, or approximately $21.13 per square foot for the remainder of the lease.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;On September 3, 2014, the Company entered into an asset purchase agreement with Hy Biopharma, Inc. (&amp;#8220;Hy Biopharma&amp;#8221;) pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma&amp;#8217;s synthetic hypericin product. As consideration for the assets acquired, the Company paid $275,000 in cash and issued 184,912 shares of common stock with a fair value based on the Company&amp;#8217;s stock price on the date of grant of $3,750,000. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in the Company&amp;#8217;s research and development activities and do not have alternative future use pursuant to generally accepted accounting principles in the United States. Provided all future success-oriented milestones are attained, the Company will be required to make additional payments of up to $10.0 million, if and when achieved. Payments will be payable in restricted securities of the Company not to exceed 19.9% ownership of Company&amp;#8217;s outstanding stock. As of September 30, 2016, no milestone or royalty payments have been paid or accrued.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In February 2007, the Company&amp;#8217;s Board of Directors authorized the issuance of 50,000 shares of the Company&amp;#8217;s common stock to Dr. Schaber immediately prior to the completion of a transaction, or series or a combination of related transactions, negotiated by its Board of Directors whereby, directly or indirectly, a majority of its capital stock or a majority of its assets are transferred from the Company and/or its stockholders to a third party. Dr. Schaber&amp;#8217;s amended employment agreement includes the Company&amp;#8217;s obligation to issue such shares if such event occurs.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 10pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As a result of the above agreements, the Company has future contractual obligations over the next five years as follows:&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tchleft" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Year&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Research and Development&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal;
 font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Property and Other Leases&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: #cceeff; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;October 1 through December 31, 2016&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;16,667&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;39,333&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;56,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2017&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;151,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size:
 10pt;"&gt;251,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: #cceeff; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2018&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;52,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;152,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2019&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: #cceeff; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align:
 right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;416,667&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;242,333&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;659,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 11. Operating Segments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company maintains two active operating segments:&amp;#160;BioTherapeutics and Vaccines/BioDefense.&amp;#160;Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;8,754,418&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;6,756,388&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,972&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;286,628&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;8,768,390&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,043,016&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Income (Loss) from Operations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;1,263,709&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;807,164&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight:
 bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;(4,487,988&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(7,674,381&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,885,997&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,894,132&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(7,110,276&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(10,761,349&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Amortization and Depreciation Expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;39,925&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;39,625&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;199,661&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;199,196&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;7,872&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;6,966&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;247,458&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;245,787&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Other Income (Expense), Net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1,209,887&lt;/td&gt;&lt;td style="text-align:
 left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,437,505&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Share-Based Compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;111,960&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;114,920&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;148,244&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;193,926&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;394,277&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;411,304&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;654,481&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;720,150&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Identifiable Assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;2,123,676&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,025,220&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;76,183&lt;/td&gt;&lt;td style="text-align: left; font-weight:
 bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;204,308&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;5,187,263&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;5,724,720&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,387,122&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;6,954,248&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 10pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 9. Operating Segments&lt;/b&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 10pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="203" valign="bottom" style="background: white; padding: 0in; width: 152pt;" colspan="7"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Contract/Grant Revenue&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p
 class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;2,959,254&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;3,879,675&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;2,959,254&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;3,879,675&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Income (Loss) from Operations&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle"
 style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;239,012&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;653,415&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;(908,086&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family:
 timesnewromanpsstd-regular; font-size: 10pt;"&gt;(959,065&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(829,743&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(964,016&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(1,498,817&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(1,269,666&lt;/p&gt;
&lt;/td&gt;
&lt;td
 width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;Amortization and Depreciation Expense&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom"
 style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;10,090&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;10,093&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;10,313&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;50,673&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;2,063&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal;
 font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,074&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;22,466&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;62,840&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font
 style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Other Income (Expense), Net&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(174,400&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;4,044,014&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height:
 normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px;
 font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;25,164&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;19,344&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;30,496&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;29,180&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;61,590&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white;
 border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;86,400&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;117,250&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;134,924&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="203" valign="bottom" style="background: white; padding: 0in; width: 152pt;" colspan="7"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Nine Months Ended&lt;br /&gt;September 30,&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border:
 currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Contract/Grant Revenue&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;8,750,291&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,781,816&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td
 width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;13,972&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;8,750,291&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,795,788&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family:
 minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Income (Loss) from Operations&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;1,291,123&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,040,627&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;(2,822,766&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(3,094,883&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(2,882,836&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding:
 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(2,808,428&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(4,414,479&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(4,862,684&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color:
 windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;Amortization and Depreciation Expense&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;30,150&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;29,820&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size:
 10pt;"&gt;&lt;b&gt;31,309&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;148,913&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;6,443&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,763&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;67,902&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in
 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;184,496&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Other Income (Expense), Net&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;1,499,055&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(909,984&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt
 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;77,393&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;63,280&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;96,313&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular;
 font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;88,615&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;280,229&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;262,217&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;453,935&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom"
 style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;414,112&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p align="left" class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 10pt 0in; text-align: left; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 4pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;As of September 30, 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;As of&lt;br /&gt;December 31, 2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Identifiable Assets&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88"
 valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;1,801,149&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,123,676&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;56,555&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;76,183&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;5,896,100&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,187,263&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image:
 none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;7,753,804&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;7,387,122&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 12. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company entered into a purchase agreement with Lincoln Park on March 22, 2016 pursuant to which Lincoln Park has committed to purchase up to $12 million of the Company&amp;#8217;s common stock.&amp;#160;&amp;#160;Concurrently with the execution of the purchase agreement, the Company issued 10,000 shares of its common stock to Lincoln Park as a partial fee for its commitment to purchase shares of the Company&amp;#8217;s common stock under the purchase agreement. The shares that may be sold pursuant to the purchase agreement may be sold by the Company to Lincoln Park at the Company&amp;#8217;s discretion from time to time over the remaining term of approximately 36 months, once the registration statement registering the resale of the shares of common stock sold to Lincoln Park under the purchase agreement is declared effective by the SEC.&amp;#160;&amp;#160;The purchase price for the shares that the Company may sell to Lincoln Park under the purchase agreement will fluctuate based on the price of the Company&amp;#8217;s common stock.&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has the right to control the timing and amount of any sales of its shares to Lincoln Park, except that, pursuant to the terms of the agreements with Lincoln Park, the Company would be unable to sell shares to Lincoln Park that would cause Lincoln Park to beneficially own more than 4.99% of the Company&amp;#8217;s issued and outstanding common stock.&amp;#160;&amp;#160;Sales of the Company&amp;#8217;s common stock, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by the Company.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s board of directors and stockholders approved a one-for-ten reverse split of the Company&amp;#8217;s common stock, which was effected on October 7, 2016. The reverse split combined every ten shares of the Company&amp;#8217;s issued and outstanding common stock into one share of common stock and correspondingly adjusted the number of shares issuable and the exercise prices under its outstanding options and warrants. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share. The reverse split was effective upon filing of the Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation on October 7, 2016. The Company has reflected the effect of the one-for-ten reverse split of its common stock (and the corresponding adjustment of the number of shares issuable and the exercise prices under its outstanding options and warrants) in these financial statements as if it had occurred at the beginning of the earliest period presented.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p class="h2" style="font: bold 10pt/12pt timesnewromanpsstd-bold; margin: 10pt 0in 0pt; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; page-break-after: avoid; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 10. Subsequent Events&lt;/b&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 6pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;During November 2016, the Company and the holders of the issued and outstanding common stock purchase warrants dated June 25, 2013 issued in connection with the Company&amp;#8217;s June 2013 registered public offering agreed to amend the terms of those common stock purchase warrants. According to the terms of the Amendment to the Common Stock Purchase Warrant (the &amp;#8220;Amendment&amp;#8221;), the exercise price per share of the common stock under those warrants (after giving effect to the one-for-ten reverse stock split effective October 7, 2016) was reduced from $5.10 per share to $0.80 per share. In addition, the Amendment permits the holders to exercise those warrants by means of a cashless exercise in which the holders shall be entitled to receive shares based on a formula in the Amendment and the &amp;#8220;down round&amp;#8221; provision was eliminated. As a result of the Amendment, the warrant liability, as described in Note 5, Warrant Liability, was remeasured as of the date of the modification, which resulted in an approximate $430,000 decrease in the carrying value of the warrant liability, which was recognized in the statement of operations on the date of the modification. The warrant liability was then reclassified to equity as the amended terms of the warrants qualified them to be accounted for as equity instruments. Of the 303,694 shares of common stock that remained issuable upon the exercise of such warrants as of September 30, 2016, warrants to purchase a total of 42,444 shares were subsequently exchanged on a cashless exercise basis, and as a result, 33,978 shares of common stock were issued through November 9, 2016.&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Operating Segments&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: BioTherapeutics and Vaccines/BioDefense.&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&lt;u&gt;Operating Segments&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: BioTherapeutics and Vaccines/BioDefense.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&lt;u&gt;Cash and cash equivalents&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<sngx:GrantsReceivablePolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Contracts and Grants Receivable&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Contracts and grants receivable consist of unbilled amounts due from various grants from the NIH and contracts from BARDA and NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.&lt;/p&gt;&lt;/div&gt;</sngx:GrantsReceivablePolicyTextBlock>
<sngx:GrantsReceivablePolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&lt;u&gt;Contracts and Grants Receivable&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;Contracts and grants receivable consist of unbilled amounts due from various grants from the NIH and contracts from BARDA and NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.&lt;/p&gt;</sngx:GrantsReceivablePolicyTextBlock>
<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Intangible Assets&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;One of the most significant estimates or judgments that the Company makes is whether to capitalize or expense patent and license costs. The Company makes this judgment based on whether the technology has alternative future uses, as defined in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;. Based on this consideration, the Company capitalizes payments made to legal firms that are engaged in filing and protecting rights to intellectual property and rights for its current products in both the domestic and international markets. The Company believes that patent rights are one of its most valuable assets. Patents and patent applications are a key component of intellectual property, especially in the early stage of product development, as their purchase and maintenance gives the Company access to key product development rights from Soligenix&amp;#8217;s academic and industry partners. These rights can also be sold or sub-licensed as part of its strategy to partner its products at each stage of development as the intangible assets have alternative future use. The legal costs incurred for these patents consist of work associated with filing new patents designed to protect, preserve and maintain the Company&amp;#8217;s rights, and perhaps extend the lives of the patents. The Company capitalizes such costs and amortizes intangibles on a straight-line basis over their expected useful life &amp;#8211; generally a period of 11 to 16 years.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;These intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable or if the underlying program is no longer being pursued. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and carrying value of the related asset or group of assets. No such write downs have occurred during the years ended December 31, 2015 and 2014.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company did not capitalize any patent related costs during the years ended December 31, 2015 or 2014.&lt;/p&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Intangible Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;One of the most significant estimates or judgments that the Company makes is whether to capitalize or expense patent and license costs. The Company makes this judgment based on whether the technology has alternative future uses, as defined in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;. Based on this consideration, the Company capitalizes payments made to legal firms that are engaged in filing and protecting rights to intellectual property and rights for its current products in both the domestic and international markets. The Company believes that patent rights are one of its most valuable assets. Patents and patent applications are a key component of intellectual property, especially in the early stage of product development, as their purchase and maintenance gives the Company access to key product development rights from Soligenix&amp;#8217;s academic and industry partners. These rights can also be sold or sub-licensed as part of its strategy to partner its products at each stage of development as the intangible assets have alternative future use. The legal costs incurred for these patents consist of work associated with filing new patents designed to protect, preserve and maintain the Company&amp;#8217;s rights, and perhaps extend the lives of the patents. The Company capitalizes such costs and amortizes intangibles on a straight-line basis over their expected useful life &amp;#8211; generally a period of 11 to 16 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company did not capitalize any patent related costs during the nine months ended September 30, 2016 and 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;These intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable or if the underlying program is no longer being pursued. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and carrying value of the related asset or group of assets. No such write downs have occurred during the nine months ended September 30, 2016 and 2015.&lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Office furniture and equipment and intangible assets are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company did not record any impairment of long-lived assets for the years ended December 31, 2015 or 2014.&lt;/p&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Office furniture and equipment and intangible assets are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company did not record any impairment of long-lived assets for the nine months ended September 30, 2016 and 2015.&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;FASB ASC 820 &amp;#8212;&amp;#160;&lt;i&gt;Fair Value Measurements and Disclosures,&amp;#160;&lt;/i&gt;defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on December 31, 2015. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px; padding-bottom: 7.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 24px; padding-bottom: 7.5pt; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 7.5pt; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1 &amp;#8212; Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-bottom: 7.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 7.5pt; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-bottom: 7.5pt; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2 &amp;#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-family: 'times new roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3 &amp;#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, accounts payable, notes payable and accrued compensation approximate their fair value based on the short-term maturity of these instruments. The Company recognizes all derivative
 financial
 instruments as assets or liabilities in the financial statements and measures them at fair value with changes in fair value reflected as current period income or loss unless the derivatives qualify as hedges. As a result, certain warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering were accounted for as derivatives. See Note 5,&amp;#160;&lt;i&gt;Warrant Liability&lt;/i&gt;.&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;FASB ASC 820 &amp;#8212;&amp;#160;&lt;i&gt;Fair Value Measurements and Disclosures,&amp;#160;&lt;/i&gt;defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on September 30, 2016. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 1 &amp;#8212; Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 2 &amp;#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px;
 letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 3 &amp;#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, accounts payable, notes payable and accrued compensation approximate their fair value based on the short-term maturity of these instruments. The Company recognizes all derivative financial instruments as assets or liabilities in the financial statements and measures them at fair value with changes in fair value reflected as current period income or loss unless the derivatives qualify as hedges. As a result, certain warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering were accounted for as derivatives. See Note 5,&amp;#160;&lt;i&gt;Warrant Liability&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s revenues are primarily generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants.&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company&amp;#8217;s revenues are primarily generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Research and development costs are charged to expense when incurred in accordance with FASB ASC 730,&lt;i&gt;&amp;#160;Research and Development&lt;/i&gt;. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Purchased in-process research and development expense represents the value assigned or paid for acquired research and development for which there is no alternative future use as of the date of acquisition.&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;Research and development costs are charged to expense when incurred in accordance with FASB ASC 730,&lt;i&gt;&amp;#160;Research and Development&lt;/i&gt;. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Purchased in-process research and development expense represents the value assigned or paid for acquired research and development for which there is no alternative future use as of the date of acquisition.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<sngx:AccountingWarrantsPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Accounting for Warrants&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considered FASB ASC 815,&amp;#160;&lt;i&gt;Evaluating Whether an Instrument is Considered Indexed to an Entity&amp;#8217;s Own Stock&lt;/i&gt;, which provides guidance for determining whether an equity-linked financial instrument (or embedded feature) issued by an entity is indexed to the entity&amp;#8217;s stock, and, therefore, qualifying for the first part of the scope exception in paragraph 815-10-15. The Company evaluated the provisions in its outstanding warrants and determined that warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering contains provisions that protect holders from a decline in the issue price of the Company&amp;#8217;s common stock (or &amp;#8220;down-round&amp;#8221; provisions) and contain net settlement provisions. Consequently, these warrants are recognized as liabilities at their fair value on the date of grant and remeasured at fair value on each reporting date. All other warrants issued were indexed to the Company&amp;#8217;s stock and therefore are accounted for as equity instruments for 2015 and 2014.&lt;/p&gt;&lt;/div&gt;</sngx:AccountingWarrantsPolicyTextBlock>
<sngx:AccountingWarrantsPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&lt;u&gt;Accounting for Warrants&lt;/u&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;The Company considered FASB ASC 815,&amp;#160;&lt;i&gt;Evaluating Whether an Instrument is Considered Indexed to an Entity&amp;#8217;s Own Stock&lt;/i&gt;, which provides guidance for determining whether an equity-linked financial instrument (or embedded feature) issued by an entity is indexed to the entity&amp;#8217;s stock and, therefore, qualifying for the first part of the scope exception in paragraph 815-10-15. The Company evaluated the provisions and determined that warrants issued in connection with the Company&amp;#8217;s June 2013 registered public offering contain provisions that protect holders from a decline in the issue price of the Company&amp;#8217;s common stock (or &amp;#8220;down-round&amp;#8221; provisions) and contain net settlement provisions. Consequently, these warrants are recognized as liabilities at their fair value on the date of grant and remeasured at fair value on each reporting date. All other warrants issued were indexed to the Company&amp;#8217;s stock and therefore are accounted for as equity instruments for 2016 and 2015.&lt;/p&gt;</sngx:AccountingWarrantsPolicyTextBlock>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="underline" style="text-decoration: underline;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees vest 25% on the grant date, then 25% each subsequent year for a period of three years. Stock options vest over each three-month period from the date of issuance to the end of the three year period. These options have a ten year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed. Typically these instruments vest upon issuance and therefore the entire share-based compensation expense is recognized upon issuance to the vendors and/or consultants.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Share-based compensation expense for options, warrants and shares of common stock granted to non-employees has been determined in accordance with FASB ASC 505-50,&amp;#160;&lt;i&gt;Equity-Based Payments to Non-Employees&lt;/i&gt;, and represents the fair value of the consideration received, or the fair value of the equity instruments issued, whichever may be more reliably measured. For options that vest over future periods, the fair value of options granted to non-employees is amortized as the options vest. The fair value is remeasured each reporting period until performance is complete.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;For the year ended December 31, 2015 the Company issued 60,534 stock options at a weighted average exercise price of $11.90 per share. The fair value of options issued during the years ended December 31, 2015 and 2014 was estimated to be $12.20 and $14.80 per share, respectively, using the Black-Scholes option-pricing model and the following assumptions:&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;a dividend yield of 0%;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;an expected life of 4 years;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;volatilities ranging from 121% &amp;#8211; 141% and 128% &amp;#8211; 165% for 2015 and 2014, respectively;&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;forfeitures at a rate of 12%; and&lt;/p&gt;
&lt;p class="blm" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt 48pt; text-align: justify; color: black; text-transform: none; text-indent: -24pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font class="bullet"&gt;&amp;#8226;&lt;/font&gt;&lt;font class="bullet"&gt;&lt;font style="font-size: 8.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/font&gt;&amp;#160;risk-free interest rates ranging from .98% to 1.53% and 1.05% to 1.43% for 2015 and 2014, respectively.&lt;/p&gt;
&lt;p class="textflush" style="font: 10pt/12pt timesnewromanpsstd-regular; margin: 8pt 0in 0pt; text-align: justify; color: black; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The weighted average fair value of each option grant made during 2015 and 2014 was estimated on the date of each grant using the Black-Scholes option pricing model and amortized ratably over the option vesting periods, which approximates the service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees vest 25% on the grant date, then 25% each subsequent year for a period of three years. Stock options vest over each three-month period from the date of issuance to the end of the three year period. These options have a ten year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed. Typically these instruments vest upon issuance and therefore the entire share-based compensation expense is recognized upon issuance to the vendors and/or consultants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Share-based compensation expense for options, warrants and shares of common stock granted to non-employees has been determined in accordance with FASB ASC 505-50,&amp;#160;&lt;i&gt;Equity-Based Payments to Non-Employees&lt;/i&gt;, and represents the fair value of the consideration received, or the fair value of the equity instruments issued, whichever may be more reliably measured. For options that vest over future periods, the fair value of options granted to non-employees is amortized as the options vest. The fair value is remeasured each reporting period until performance is complete.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For the nine months ended September 30, 2016 and 2015, the Company issued stock options at a weighted average exercise price of $7.72 and $14.40 per share, respectively. The fair value of options issued during the nine months ended September 30, 2016 and 2015 was estimated using the Black-Scholes option-pricing model and the following assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;a dividend yield of 0%;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt;
 text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;an expected life of 4 years;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;volatility of 116% for 2016 and ranging from 136%-141% for 2015;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;forfeitures at a rate of 12%; and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 18pt; text-indent: 0pt; font-stretch: normal;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;risk-free interest rates ranging from 0.96%-1.52% and 0.99%-1.34% for 2016 and 2015, respectively.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The fair value of each option grant made during 2016 and 2015 was estimated on the date of each grant using the Black-Scholes option pricing model and amortized ratably over the option vesting periods, which approximates the service period.&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company&amp;#8217;s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods.&amp;#160;Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2015 and 2014. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at December 31, 2015 and 2014.&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including the Company&amp;#8217;s current and past performance, the market environment in which the Company operates, the utilization of past tax credits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. No current or deferred income taxes have been provided through September 30, 2016 due to the net operating losses incurred by the Company since its inception. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2016 and 2015. Additionally, the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at September 30, 2016 and December 31, 2015.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Earnings Per Share&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) excludes dilution and is computed by dividing income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period, as adjusted for the reverse stock split of one-for-ten effective October 7, 2016. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#160;&lt;b&gt;For the Year Ended&lt;/b&gt;&amp;#160;&amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;For the Year Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#160;&lt;b&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2015&lt;/b&gt;&amp;#160;&amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Net loss for basic earnings per share&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;(7,831,230&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(6,706,972&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Less change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,436,195&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Net loss for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(7,831,230&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(10,143,167&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Denominator:&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Weighted-average basic common shares outstanding&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,606,577&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,063,842&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Assumed conversion of dilutive securities:&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Common stock purchase warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;294,652&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Denominator for diluted earnings per share &amp;#8211; adjusted weighted-average shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,606,577&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,358,494&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Basic net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;3.2 5)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;4.3 0)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation because their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: center; font-weight: bold;" colspan="2"&gt;For the Year Ended&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight:
 bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;For the Year Ended&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Common stock purchase warrants&lt;/td&gt;&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;492,612&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;254,614&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;276,861&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;248,828&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;769,473&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;503,442&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Shares issuable upon the exercise of options and warrants outstanding at December 31, 2015 and 2014 were 276,861 and 248,828 shares issuable upon the exercise of options, and 492,612 and 726,950 shares issuable upon the exercise of warrants, respectively. The weighted average exercise price of the Company&amp;#8217;s stock options and warrants outstanding at December 31, 2015 were $21.30 and $7.40 per share, respectively.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Earnings Per Share&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) excludes dilution and is computed by dividing income (loss) available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual market price can have a variety of results for each period presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: center; text-decoration: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: center; text-decoration: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Nine Months Ended&lt;br /&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;Numerator:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Net income/(loss) for basic earnings per share&lt;/td&gt;
&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;(1,673,217&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;2,774,348&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-weight: bold;"&gt;(2,915,424&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;(5,772,668&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0pt;
 padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Less change in fair value of warrant liability&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,047,742&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,109,192&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Net loss for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,673,217&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,273,394&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(4,024,616&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(5,772,668&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;Denominator:&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Weighted-average basic common shares outstanding&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;b&gt;3,432,081&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,648,240&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;b&gt;3,245,653&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,553,930&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Assumed conversion of dilutive securities:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Common stock purchase warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;180,818&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;102,184&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Denominator for diluted earnings per share &amp;#8211; adjusted weighted-average shares&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;3,432,081&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,829,058&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;3,347,837&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,553,930&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;Basic net income (loss) per share&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.05&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.90&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(2.26&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;Diluted net loss per share&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.45&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1.20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(2.26&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation because their effect would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left; font-family: 'times new roman', serif;"&gt;Common stock purchase warrants&lt;/td&gt;
&lt;td style="width: 16px; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', serif; font-weight: bold;"&gt;492,614&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', serif;"&gt;188,920&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', serif; font-weight: bold;"&gt;188,920&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', serif;"&gt;492,614&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;Stock options&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;299,752&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;230,074&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times
 new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;299,752&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;230,074&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;792,366&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;418,994&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;488,672&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;722,686&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The weighted average exercise price of the Company&amp;#8217;s stock options and warrants outstanding at September 30, 2016 were $18.20 and $7.38 per share, respectively, and at September 30, 2015 were $23.30 and $8.00 per share, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Use of Estimates and Assumptions&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions such as the fair value of warrants and stock options and the useful life of intangibles that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Use of Estimates and Assumptions&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions such as the fair value of warrants and stock options and recovery of the useful life of intangibles that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2014, FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-15, &amp;#8220;&lt;i&gt;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&amp;#8221;&amp;#160;&lt;/i&gt;The amendments in this ASU are intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. Specifically, this ASU provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#8217;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard will have on the Company's consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="color: #252525;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &amp;#8220;&lt;i&gt;Leases&lt;/i&gt;&amp;#8221; (topic 842)&lt;i&gt;.&amp;#160;&lt;/i&gt;&lt;/font&gt;The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.&amp;#160;&lt;font style="color: #252525;"&gt;The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the update is permitted.&amp;#160;&lt;/font&gt;The Company&lt;font style="color: #252525;"&gt;&amp;#160;&lt;/font&gt;is evaluating the impact of&lt;font style="color: #252525;"&gt;&amp;#160;&lt;/font&gt;the adoption of this update on our consolidated financial statements and related disclosures.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In August 2014, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-15, &amp;#8220;Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&amp;#8221; The amendments in this ASU are intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. Specifically, this ASU provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#8217;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact the adoption of this standard will have on the Company's consolidated financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &amp;#8220;Leases&amp;#8221; (topic 842). The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the update is permitted.&amp;#160;The Company&amp;#160;is evaluating the impact of&amp;#160;the adoption of this update on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, &amp;#8220;Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, and intends to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. It is effective for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption is permitted. The Company is currently evaluating the impact of adoption of this update on our consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#160;&lt;b&gt;For the Year Ended&lt;/b&gt;&amp;#160;&amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;For the Year Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;&amp;#160;&lt;b&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2015&lt;/b&gt;&amp;#160;&amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Net loss for basic earnings per share&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;(7,831,230&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(6,706,972&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Less change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,436,195&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Net loss for diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(7,831,230&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(10,143,167&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Denominator:&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Weighted-average basic common shares outstanding&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,606,577&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,063,842&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Assumed conversion of dilutive securities:&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Common stock purchase warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:
 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width:
 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;294,652&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Denominator for diluted earnings per share &amp;#8211; adjusted weighted-average shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,606,577&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,358,494&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Basic net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;3.2 5)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(3.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(&lt;font style="font-family: 'times new roman', serif; font-size: 10pt;"&gt;4.3 0)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: center; text-decoration: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: center; text-decoration: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Nine Months Ended&lt;br /&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold; text-decoration: none; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;Numerator:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Net income/(loss) for basic earnings per share&lt;/td&gt;
&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;(1,673,217&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;2,774,348&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-weight: bold;"&gt;(2,915,424&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;(5,772,668&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Less change in fair value of warrant liability&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,047,742&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,109,192&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Net loss for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;
 font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,673,217&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,273,394&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(4,024,616&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(5,772,668&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;Denominator:&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Weighted-average basic common shares outstanding&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;b&gt;3,432,081&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,648,240&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;b&gt;3,245,653&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,553,930&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Assumed conversion of dilutive securities:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Common stock purchase warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;180,818&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;102,184&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Denominator for diluted earnings per share &amp;#8211; adjusted weighted-average shares&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;3,432,081&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,829,058&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;b&gt;3,347,837&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,553,930&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;Basic net income (loss) per share&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.05&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.90&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(2.26&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;Diluted net loss per share&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.45&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1.20&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(2.26&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;For the Year Ended&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;For the Year Ended&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Common stock purchase warrants&lt;/td&gt;&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;492,612&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;254,614&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;276,861&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;248,828&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;769,473&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;503,442&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
<us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 815px; text-align: left; font-family: 'times new roman', serif;"&gt;Common stock purchase warrants&lt;/td&gt;
&lt;td style="width: 16px; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', serif; font-weight: bold;"&gt;492,614&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', serif;"&gt;188,920&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', serif; font-weight: bold;"&gt;188,920&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', serif;"&gt;492,614&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;Stock options&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;299,752&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;230,074&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;299,752&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;
 font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;230,074&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;792,366&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;418,994&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;488,672&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;722,686&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', serif;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;div&gt;Weighted Average&lt;/div&gt;&lt;div&gt;Remaining Amortization&lt;/div&gt;&lt;div&gt;Period (Years)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Net Book Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;" colspan="5"&gt;December 31, 2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 801.67px; padding-left: 10pt;"&gt;Licenses&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: center;"&gt;3.8&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;462,234&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;333,732&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;128,502&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Patents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;1.1&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,893,185&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,832,955&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;60,230&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,355,419&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,166,687&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;188,732&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold;"&gt;December 31, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;Licenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;4.7&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align:
 right;"&gt;462,234&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td
 style="text-align: right;"&gt;306,495&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;155,739&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Patents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,893,185&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,638,975&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;254,210&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;2.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,355,419&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,945,470&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;409,949&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="14%" valign="bottom" style="background: white; padding: 0in; width: 89px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Cost&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="14%" valign="bottom" style="background: white; padding: 0in; width: 87px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Accumulated Amortization&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="14%" valign="bottom" style="background: white; padding: 0in; width: 87px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Net Book&lt;br /&gt;Value&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&lt;u&gt;September 30, 2016&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 8px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 81px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Licenses&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 8px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 81px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;462,234&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;354,179&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;108,055&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Patents&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 8px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,893,185&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,858,932&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;34,253&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 8px; border-bottom-color:
 windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,355,419&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,213,111&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;142,308&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&lt;u&gt;December 31, 2015&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 8px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 81px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 7px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 80px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Licenses&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p
 class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 8px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 81px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;462,234&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;333,732&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 80px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;128,502&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: #cceeff; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Patents&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 8px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,893,185&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,832,955&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;60,230&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="51%" valign="bottom" style="background: white; padding: 0in; width: 308px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 8px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 81px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,355,419&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,166,687&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 9px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 7px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 80px; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;188,732&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Amortization Expense&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1378px; text-align: left;"&gt;2016&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$61,800&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$61,800&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$37,300&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2019&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$27,832&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: white; padding: 0in; width: 500px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="15%" valign="bottom" style="background: white; padding: 0in; width: 90px;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Amortization Expense&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: #cceeff; padding: 0in; width: 500px;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;October 1 thru December 31, 2016&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;15,376&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: white; padding: 0in; width: 500px;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2017&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;61,800&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: #cceeff; padding: 0in; width: 500px;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2018&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: #cceeff; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: #cceeff; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;37,300&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="83%" valign="bottom" style="background: white; padding: 0in; width: 500px;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2019&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 10px;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="background: white; padding: 0in; width: 7px;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13%" valign="bottom" style="background: white; padding: 0in; width: 83px;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;27,832&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
<sngx:ScheduleOfAssumptionsUsedInValuationOfWarrantsIssuedTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; font-stretch: normal;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Initial Measurement June 25,&lt;br /&gt;2013&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2013&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercised During 2015&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December 31,&amp;#160;&lt;br /&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 627px; text-align: left;"&gt;Number of shares underlying the warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;541,685&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;530,944&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;472,336&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;168,643&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;303,693&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;16.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;16.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.10&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.10&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.10&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;140&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;135&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;128&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;117-119% &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;98&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.49&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.75&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.38&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;.81-1.06% &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected warrant life (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3.5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;3.01-3.33 &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.48&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock price&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;9.60&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;18.00&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;9.80&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;$ 16.90-$22.20 &amp;#160; &amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;11.30&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sngx:ScheduleOfAssumptionsUsedInValuationOfWarrantsIssuedTableTextBlock>
<sngx:ScheduleOfAssumptionsUsedInValuationOfWarrantsIssuedTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;September 30, 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;December 31, 2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Number of shares underlying the warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;303,694&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;303,694&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Exercise price&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5.10&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom"
 style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5.10&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Volatility&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;90&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;98&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;0.68&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1.19&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Expected dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8"
 valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;0&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;0&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Expected warrant life (years)&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1.73&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: white; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2.48&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: white; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Stock Price&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;7.70&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal;
 padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="75" valign="bottom" style="background: #cceeff; padding: 0in; width: 56.35pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;11.30&lt;/p&gt;
&lt;/td&gt;
&lt;td width="13" valign="bottom" style="background: #cceeff; padding: 0in; width: 9.65pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</sngx:ScheduleOfAssumptionsUsedInValuationOfWarrantsIssuedTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; font-stretch: normal;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Decrease from Warrants Exercised in 2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Increase in Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 815px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Warrant liability&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 16px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 16px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 142px; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;3,789,562&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 16px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 16px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 16px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 142px; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;(2,557,331&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 16px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;)&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 15px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 15px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 141px; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;1,201,870&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 15px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 15px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 15px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13.33px/normal 'times new roman', times, serif; width: 141px; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;2,434,101&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="240" valign="bottom" style="background: white; padding: 0in; width: 2.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;December 31, 2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Decrease from Warrants Exercised in 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Decrease&lt;br /&gt;in Fair Value&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;September 30, 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="240" valign="bottom" style="background: #cceeff; padding: 0in; width: 2.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Warrant liability&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,434,101&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 1in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt;
 border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,109,192&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p align="left" class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;1,324,909&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="240" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="8" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="88" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="96" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="8" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="88" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="11" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="8" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;td width="88" style="padding: 0pt; border: currentcolor; border-image: none;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; padding-bottom: 1.5pt;"&gt;State&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(488,933&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(616,872&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(488,933&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(616,872&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;31,216,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;29,594,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Orphan drug and research and development credit carry forwards&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,909,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,556,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Equity based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,923,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,049,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Intangibles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,090,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,140,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold;"&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;40,138,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;37,339,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(40,138,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(37,339,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Income tax loss at federal statutory rate&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;(34.00&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;)%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;(34.00&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;)%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;State tax benefits, plus sale of NJ NOLs, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(40.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(40.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;34.12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;31.58&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(5.88&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(8.42&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EquityIncentivePlanMember">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left; font-weight: bold;"&gt;Shares available for grant at plan approval&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;300,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(47,700&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;Shares available for grant at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;252,300&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Warrant Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; font-weight: bold;"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;815,653&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;21.70&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;116,932&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(58,608&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;16.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(147,027&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;34.90&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold;"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;726,950&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;11.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(174,643&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.40&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(59,695&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;55.90&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;Balance at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;492,612&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7.40&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Options Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; font-weight: bold; padding-bottom: 4pt;"&gt;Balance at December 31, 2013&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; border-bottom: 4pt double black; text-align: right;"&gt;205,151&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; border-bottom: 4pt double black; text-align: right;"&gt;26.30&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;63,750&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;17.90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(3,667&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;7.70&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;(16,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;31.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;248,828&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;24.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;60,534&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;11.90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(3,312&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&amp;#160;&amp;#160;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;(29,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;31.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;Balance at December 31, 2015&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;276,861&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;21.30&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_ShareBasedCompensationMember">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: italic; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Share-based Compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left;"&gt;Research and Development&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;260,204&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;308,847&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;General and Administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;394,277&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;411,303&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;654,481&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;720,150&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Price&lt;/b&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercisable Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: center;"&gt;$5.10-$5.30&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;2.4&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;381,180&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;381,180&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;$14.80-$20.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;111,432&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;111,432&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2.7&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;492,612&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;492,612&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Weighted Average Remaining&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Contractual Life in Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: 1.5pt solid black;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif; margin: 0px; text-align: center;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: center;"&gt;$3.00-$22.00&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;8.03&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;217,084&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;148,443&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center;"&gt;$22.60-$41.00&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.36&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;17,477&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;17,477&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;$46.40-$94.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;3.22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;42,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 1.5pt solid black; text-align: right;"&gt;42,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;7.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;276,861&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: 4pt double black; text-align: right;"&gt;208,220&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
<us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;Year&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Research and Development&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Property and Other Leases&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 800.8px; text-align: left; text-indent: 0pt; font-stretch: normal;"&gt;2016&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12.8px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12.8px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 112.8px; text-align: right; font-stretch: normal;"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12.8px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12.8px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12.8px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 112.8px; text-align: right; font-stretch: normal;"&gt;157,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 112px; text-align: right; font-stretch: normal;"&gt;257,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; width: 12px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; text-indent: 0pt; font-stretch: normal;"&gt;2017&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;151,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;251,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; text-indent: 0pt; font-stretch: normal;"&gt;2018&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;52,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;152,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; text-indent: 0pt; font-stretch: normal;"&gt;2019&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; font-stretch: normal;"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; font-stretch: normal;"&gt;2020&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; text-indent: 0pt; padding-bottom: 4pt; font-stretch: normal;"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;500,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;360,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;860,000&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
<us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tchleft" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Year&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Research and Development&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Property and Other Leases&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: #cceeff; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;October 1 through December 31, 2016&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;16,667&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;39,333&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;56,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2017&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width:
 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;151,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;251,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: #cceeff; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2018&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;52,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;152,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2019&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign"
 style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: #cceeff; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;100,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="336" valign="bottom" style="background: white; padding: 0in; width: 3.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;416,667&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none
 double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;242,333&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;659,000&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
<us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;8,754,418&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;6,756,388&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,972&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;286,628&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;8,768,390&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,043,016&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Income (Loss) from Operations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;1,263,709&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;807,164&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;(4,487,988&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(7,674,381&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,885,997&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,894,132&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight:
 bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(7,110,276&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(10,761,349&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Amortization and Depreciation Expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;39,925&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;39,625&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;199,661&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;199,196&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;7,872&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;6,966&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;247,458&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;245,787&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Other Income (Expense), Net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1,209,887&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,437,505&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;Share-Based Compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td
 style="text-align: right; font-weight: bold;"&gt;111,960&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;114,920&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;148,244&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;193,926&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;394,277&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;411,304&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;654,481&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;720,150&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Identifiable Assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; padding-left: 10pt;"&gt;Vaccines/BioDefense&lt;/td&gt;&lt;td style="width: 16px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-weight: bold;"&gt;2,123,676&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,025,220&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt;"&gt;BioTherapeutics&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold;"&gt;76,183&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;204,308&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;5,187,263&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;5,724,720&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 20pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;
 font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,387,122&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;6,954,248&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
<us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="203" valign="bottom" style="background: white; padding: 0in; width: 152pt;" colspan="7"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Contract/Grant Revenue&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom"
 style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;2,959,254&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;3,879,675&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#8212;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family:
 timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;2,959,254&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;3,879,675&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Income (Loss) from Operations&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom"
 style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;239,012&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;653,415&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;(908,086&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(959,065&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font
 style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(829,743&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(964,016&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(1,498,817&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(1,269,666&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font
 style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;Amortization and Depreciation Expense&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;10,090&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td
 width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;10,093&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;10,313&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;50,673&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;2,063&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family:
 timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,074&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;22,466&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;62,840&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in
 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Other Income (Expense), Net&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(174,400&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;4,044,014&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor;
 border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;25,164&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular;
 font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;19,344&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;30,496&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;29,180&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;61,590&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;86,400&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color:
 black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;117,250&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;134,924&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="203" valign="bottom" style="background: white; padding: 0in; width: 152pt;" colspan="7"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;Nine Months Ended&lt;br /&gt;September 30,&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="3"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight:
 bold;"&gt;2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Contract/Grant Revenue&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;8,750,291&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,781,816&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext;
 border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#8212;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;13,972&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;8,750,291&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,795,788&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width:
 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Income (Loss) from Operations&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;1,291,123&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size:
 10pt;"&gt;1,040,627&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;(2,822,766&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodybracket" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(3,094,883&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodybracket" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(2,882,836&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(2,808,428&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule1brack" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle"
 style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;(4,414,479&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(4,862,684&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;Amortization and Depreciation Expense&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family:
 minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;30,150&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;29,820&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;31,309&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size:
 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;148,913&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;6,443&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,763&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;67,902&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black;
 line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;184,496&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Other Income (Expense), Net&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family:
 timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;1,499,055&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;(909,984&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrule2brack" style="margin: 0in; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; border: currentcolor; border-image: none; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle"
 style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;77,393&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;63,280&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;96,313&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; padding: 0in; width: 60pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px;
 font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;88,615&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;280,229&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;262,217&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;453,935&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="80" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 60pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;414,112&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt;
 color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;table class="msonormaltable" style="margin: 0px auto; border: 0px solid #000000; border-image: none; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;As of September 30, 2016&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="96" valign="bottom" style="background: white; padding: 0in; width: 1in;" colspan="2"&gt;
&lt;div style="border-style: none none solid; padding: 0in; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tch" style="margin: 0in 0in 0pt; padding: 0in 0in 0pt; border: currentcolor; border-image: none; text-align: center; color: black; line-height: normal; font-family: timesnewromanpsstd-bold; font-size: 9pt; font-weight: bold;"&gt;As of&lt;br /&gt;December 31, 2015&lt;/p&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;Identifiable Assets&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Vaccines/BioDefense&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;1,801,149&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; padding: 0in; width: 6pt;"&gt;
&lt;p align="left" class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: left; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;2,123,676&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding:
 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;BioTherapeutics&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;b&gt;56,555&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; padding: 0in; width: 6pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; padding: 0in; width: 66pt;"&gt;
&lt;p class="tbodyrightalign" style="margin: 0in 0in 0pt; text-align: right; color: black; line-height: normal; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;76,183&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: white; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbody" style="margin: 0in 0in 0pt 10pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Corporate&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;5,896,100&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: white; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: white; border-style: none none solid; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 1pt;"&gt;
&lt;p class="tbodyrule1" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;5,187,263&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td width="432" valign="bottom" style="background: #cceeff; padding: 0in; width: 4.5in;"&gt;
&lt;p class="tbodyind1" style="margin: 0in 0in 0pt 20pt; color: black; line-height: normal; text-indent: -10pt; padding-bottom: 3px; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;&lt;font style="font-family: timesnewromanpsstd-bold;"&gt;&lt;b&gt;7,753,804&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="11" valign="bottom" style="background: #cceeff; padding: 0in; width: 8pt;"&gt;
&lt;p class="noparagraphstyle" style="margin: 0in 0in 0pt; color: black; line-height: normal; font-family: minionpro-regular; font-size: 12pt;"&gt;&lt;font style="color: windowtext; font-family: timesnewromanpsstd-bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="8" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 6pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p align="left" class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor;
 border-image: none; text-align: left; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td width="88" valign="bottom" style="background: #cceeff; border-style: none none double; padding: 0in; width: 66pt; border-bottom-color: windowtext; border-bottom-width: 2.25pt;"&gt;
&lt;p class="tbodyrule2" style="margin: 0in 0in 0pt; padding: 0in; border: currentcolor; border-image: none; text-align: right; color: black; line-height: normal; font-family: timesnewromanpsstd-regular; font-size: 10pt;"&gt;7,387,122&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
<us-gaap:NumberOfOperatingSegments contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="Segments" decimals="INF">2</us-gaap:NumberOfOperatingSegments>
<us-gaap:NumberOfOperatingSegments contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="Segments" decimals="INF">2</us-gaap:NumberOfOperatingSegments>
<sngx:PercentageChangeInCashAndCashEquivalents contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="2">0.11</sngx:PercentageChangeInCashAndCashEquivalents>
<sngx:PercentageChangeInCashAndCashEquivalents contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="2">0.15</sngx:PercentageChangeInCashAndCashEquivalents>
<sngx:WorkingCapitalCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3174214</sngx:WorkingCapitalCarryingValue>
<sngx:WorkingCapitalCarryingValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2179694</sngx:WorkingCapitalCarryingValue>
<sngx:WorkingCapitalCarryingValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3319982</sngx:WorkingCapitalCarryingValue>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2434101</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">324909</us-gaap:DerivativeLiabilities>
<sngx:ChangeInWorkingCapital contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">994520</sngx:ChangeInWorkingCapital>
<sngx:ChangeInWorkingCapital contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1140288</sngx:ChangeInWorkingCapital>
<sngx:PercentageOfChangeInWorkingCapital contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="2">0.31</sngx:PercentageOfChangeInWorkingCapital>
<sngx:PercentageOfChangeInWorkingCapital contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="2">0.52</sngx:PercentageOfChangeInWorkingCapital>
<us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="-5">43000000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
<us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="-5">35100000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
<sngx:ProceedsFromNetOperatingLosses contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">488933</sngx:ProceedsFromNetOperatingLosses>
<sngx:ProceedsFromNetOperatingLosses contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">530143</sngx:ProceedsFromNetOperatingLosses>
<us-gaap:DebtInstrumentCarryingAmount contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="-5">20200000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentCarryingAmount contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_NovemberTwoThousandSixteenMember" unitRef="USD" decimals="-5">8200000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentCarryingAmount contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_MarchTwoThousandNineteenMember" unitRef="USD" decimals="-5">10400000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember">2016-04-15</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_NovemberTwoThousandSixteenMember">2016-11-30</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_CreationDateAxis_MarchTwoThousandNineteenMember">2019-03-31</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-6706972</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2774348</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-5772668</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-7831230</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1673217</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-2915424</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3436195</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4047742</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1109192</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-10143167</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1273394</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-5772668</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-7831230</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-1673217</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-4024616</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">294652</sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants>
<sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">180818</sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants>
<sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" xsi:nil="true"/>
<sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">102184</sngx:ConversionOfDilutiveSecuritiesCommonStockPurchaseWarrants>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">2358494</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">2829058</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">2553930</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">2606577</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">3432081</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">3347837</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">503442</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember" unitRef="shares" decimals="INF">254614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">248828</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">418994</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember" unitRef="shares" decimals="INF">188920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">230074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">722686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember" unitRef="shares" decimals="INF">492614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">230074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">769473</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember" unitRef="shares" decimals="INF">492612</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">276861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">792366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember" unitRef="shares" decimals="INF">492614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">299752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">488672</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_CommonStockPurchaseWarrantsMember" unitRef="shares" decimals="INF">188920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">299752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">21.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">26.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">24.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">8.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">23.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="2">11.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">7.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">21.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">21.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">7.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">19.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_RangeAxis_MinimumMember">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_RangeAxis_MaximumMember">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RangeAxis_MinimumMember">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RangeAxis_MaximumMember">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="pure" decimals="2">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="pure" decimals="2">0.12</sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
<sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="pure" decimals="2">0.12</sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
<sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="pure" decimals="2">0.12</sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<sngx:VestingPeriodOfOptionIssuedUponReElection contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">P1Y</sngx:VestingPeriodOfOptionIssuedUponReElection>
<sngx:PeriodOfStockOptionGrantedToDirectorAndEmployees contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">P10Y</sngx:PeriodOfStockOptionGrantedToDirectorAndEmployees>
<sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOptionsVestedImmediately contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="2">0.25</sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOptionsVestedImmediately>
<sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOptionsVestedLater contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="2">0.25</sngx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOptionsVestedLater>
<sngx:ExpirationOfOptionsUponTerminationOfEmployee contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">P3M</sngx:ExpirationOfOptionsUponTerminationOfEmployee>
<sngx:PeriodOfReMeasurementOfOptionPrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">P3M</sngx:PeriodOfReMeasurementOfOptionPrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EquityIncentivePlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">116932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">63750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">-477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">60534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">-47700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="shares" decimals="INF">60534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:SharePrice contextRef="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">9.60</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">18.00</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">9.80</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">14.80</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">11.30</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">12.20</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">2.22</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.69</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_May_2016T00_00_00_TO_31_May_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">7.30</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_29_Aug_2016T00_00_00_TO_29_Aug_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">6.40</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">7.70</us-gaap:SharePrice>
<sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">726950</sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments>
<sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="shares" decimals="INF">248828</sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments>
<sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">492612</sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments>
<sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="shares" decimals="INF">276861</sngx:SharesIssuableUponExerciseOfOutstandingDerivativeInstruments>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember">Stock options issued to employees vest 25% on the grant date, then 25% each subsequent year for a period of three years. Stock options vest over each three-month period from the date of issuance to the end of the three year period.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">17.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">8.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">14.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">11.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">7.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">7.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_StatementScenarioAxis_DirectorsUponReElectionMember">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_StatementScenarioAxis_PermanentEmployeesOrDirectorsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_StockOptionMember_StatementScenarioAxis_TerminatedEmployeesOrDirectorsMember">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<sngx:WeightedAverageAmortizationPeriodYears contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">P2Y7M6D</sngx:WeightedAverageAmortizationPeriodYears>
<sngx:WeightedAverageAmortizationPeriodYears contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">P4Y8M12D</sngx:WeightedAverageAmortizationPeriodYears>
<sngx:WeightedAverageAmortizationPeriodYears contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">P1Y10M24D</sngx:WeightedAverageAmortizationPeriodYears>
<sngx:WeightedAverageAmortizationPeriodYears contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">P3Y9M18D</sngx:WeightedAverageAmortizationPeriodYears>
<sngx:WeightedAverageAmortizationPeriodYears contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">P1Y1M6D</sngx:WeightedAverageAmortizationPeriodYears>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2355419</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">462234</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">1893185</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2355419</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">462234</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">1893185</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2355419</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">462234</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">1893185</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1945470</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">306495</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">1638975</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2166687</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">333732</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">1832955</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2213111</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">354179</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">1858932</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">409949</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">155739</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">254210</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">188732</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">128502</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">60230</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">142308</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">108055</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">34253</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">61800</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">15376</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">61800</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">61800</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">37300</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">37300</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">27832</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">27832</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">222563</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">55929</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">165288</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">221217</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">15589</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">46424</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="USD" decimals="-6">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember" unitRef="USD" decimals="-6">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_RiverNorthMember" unitRef="USD" decimals="-6">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember" unitRef="USD" decimals="0">2000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="USD" decimals="0">17377</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0" id="Item_108">353</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" id="Item_109">2999647</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_29_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember" unitRef="USD" decimals="0">300000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:NotesPayable contextRef="Context_As_Of_29_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember" unitRef="USD" decimals="0">282071</us-gaap:NotesPayable>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4328</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">10648</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">7281</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_29_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember" unitRef="pure" decimals="2">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<sngx:NumberOfSharesUnderlyingWarrants contextRef="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">541685</sngx:NumberOfSharesUnderlyingWarrants>
<sngx:NumberOfSharesUnderlyingWarrants contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">530944</sngx:NumberOfSharesUnderlyingWarrants>
<sngx:NumberOfSharesUnderlyingWarrants contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">472336</sngx:NumberOfSharesUnderlyingWarrants>
<sngx:NumberOfSharesUnderlyingWarrants contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">303693</sngx:NumberOfSharesUnderlyingWarrants>
<sngx:NumberOfSharesUnderlyingWarrants contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember" unitRef="shares" decimals="INF">168643</sngx:NumberOfSharesUnderlyingWarrants>
<sngx:NumberOfSharesUnderlyingWarrants contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">303694</sngx:NumberOfSharesUnderlyingWarrants>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">16.50</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">16.50</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">6.10</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">5.10</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember" unitRef="USD_per_Share" decimals="2">6.10</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">5.10</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_Custom_01_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">1.40</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">1.35</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">1.28</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.98</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember" unitRef="pure" decimals="2">0.98</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.19</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.17</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.90</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="4">0.0149</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="4">0.0175</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="4">0.0138</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="4">0.0119</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember" unitRef="pure" decimals="4">0.0119</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0106</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0081</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="4">0.0068</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">P4Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">P3Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P2Y5M23D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember">P2Y5M23D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MaximumMember">P3Y3M29D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_ExercisedWarrantsMember_RangeAxis_MinimumMember">P3Y4D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">P1Y8M23D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">3789562</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">2434101</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1324909</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<sngx:DecreaseInWarrantsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">-2557331</sngx:DecreaseInWarrantsExercised>
<sngx:DecreaseInWarrantsExercised contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1201870</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1109192</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
<sngx:AmountOfInitialWarrantLiability contextRef="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">4827788</sngx:AmountOfInitialWarrantLiability>
<sngx:AmountOfInitialWarrantLiability contextRef="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="0">4827788</sngx:AmountOfInitialWarrantLiability>
<sngx:WarrantsExercised contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_22_Jan_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">250000</sngx:WarrantsExercised>
<sngx:WarrantsExercised contextRef="Context_Custom_01_Aug_2014T00_00_00_TO_19_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">336081</sngx:WarrantsExercised>
<sngx:WarrantsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">58608</sngx:WarrantsExercised>
<sngx:WarrantsExercised contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="2">6.10</sngx:WarrantsExercised>
<sngx:WarrantsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">168643</sngx:WarrantsExercised>
<sngx:WarrantsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="2">5.10</sngx:WarrantsExercised>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_25_Jun_2013T00_00_00_TO_25_Jun_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">7.70</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-616872</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
<us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-488933</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">29594000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">31216000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3556000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">4909000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2049000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1923000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2140000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">2090000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">37339000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">40138000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">37339000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">40138000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="4">-0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="4">-0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="4">-0.0600</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="4">-0.0600</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<sngx:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateAndStatetaxes contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="4">-0.4000</sngx:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateAndStatetaxes>
<sngx:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateAndStatetaxes contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="4">-0.4000</sngx:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateAndStatetaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="4">0.3158</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="4">0.3412</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="4">-0.0842</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="4">-0.0588</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeTaxAuthorityNameAxis_NewJerseyDivisionOfTaxationMember" unitRef="USD" decimals="0">5273000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="USD" decimals="0">90891000</us-gaap:OperatingLossCarryforwards>
<us-gaap:TaxCreditCarryforwardAmount contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">4909000</us-gaap:TaxCreditCarryforwardAmount>
<sngx:TaxCreditCarryforwardExpirationDateDescription contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">Expire from 2018 to 2034</sngx:TaxCreditCarryforwardExpirationDateDescription>
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">2018-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">7788</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">6512</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember" unitRef="shares" decimals="INF">393624</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="shares" decimals="INF">2819</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">33978</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF" id="Item_110">352942</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<sngx:EquityLinePurchaseAgreementCommonStockRightToSell contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KodiakMember" unitRef="USD" decimals="-6">5000000</sngx:EquityLinePurchaseAgreementCommonStockRightToSell>
<sngx:EquityLinePurchaseAgreementCommonStockRightToSell contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KingsbrookMember" unitRef="USD" decimals="-6">4000000</sngx:EquityLinePurchaseAgreementCommonStockRightToSell>
<sngx:EquityLinePurchaseAgreementCommonStockRightToSell contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_RiverNorthMember" unitRef="USD" decimals="-6">1000000</sngx:EquityLinePurchaseAgreementCommonStockRightToSell>
<sngx:EquityLinePurchaseAgreementCommonStockRightToSell contextRef="Context_Custom_21_Mar_2016T00_00_00_TO_22_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="USD" decimals="-6">12000000</sngx:EquityLinePurchaseAgreementCommonStockRightToSell>
<sngx:EquityLinePurchaseAgreementCommonStockRightToSell contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KodiakMember" unitRef="USD" decimals="-6">5000000</sngx:EquityLinePurchaseAgreementCommonStockRightToSell>
<sngx:EquityLinePurchaseAgreementCommonStockRightToSell contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_KingsbrookMember" unitRef="USD" decimals="-6">4000000</sngx:EquityLinePurchaseAgreementCommonStockRightToSell>
<sngx:EquityLinePurchaseAgreementCommonStockRightToSell contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_RiverNorthMember" unitRef="USD" decimals="-6">1000000</sngx:EquityLinePurchaseAgreementCommonStockRightToSell>
<sngx:WeightedAveragePriceOfCommonStockPercentage contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="pure" decimals="2">0.80</sngx:WeightedAveragePriceOfCommonStockPercentage>
<sngx:EquityLinePurchaseAgreementMaximumAmountOfInvestment contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="USD" decimals="-6">3000000</sngx:EquityLinePurchaseAgreementMaximumAmountOfInvestment>
<sngx:EquityLinePurchaseAgreementInvestmentMinimumOwnershipPercentage contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="pure" decimals="4">0.0999</sngx:EquityLinePurchaseAgreementInvestmentMinimumOwnershipPercentage>
<us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="pure" decimals="2">0.03</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
<sngx:CostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="USD" decimals="0">-453162</sngx:CostAssociatedWithEquityLinePurchaseAgreement>
<sngx:CostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">453162</sngx:CostAssociatedWithEquityLinePurchaseAgreement>
<sngx:CostAssociatedWithEquityLinePurchaseAgreement contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_29_Jul_2015T00_00_00" unitRef="pure" decimals="2">0.03</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
<sngx:StockIssuedDuringPeriodShareOfVestedStockOptionsExercised contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2917</sngx:StockIssuedDuringPeriodShareOfVestedStockOptionsExercised>
<sngx:StockIssuedDuringPeriodShareOfVestedStockOptionsExercised contextRef="Context_Custom_01_Jul_2014T00_00_00_TO_31_Jul_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">750</sngx:StockIssuedDuringPeriodShareOfVestedStockOptionsExercised>
<sngx:ClosingPriceOfCommonShares contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="USD_per_Share" decimals="2">25.00</sngx:ClosingPriceOfCommonShares>
<sngx:CommonStockPurchaseAgreementDescription contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember">In November 2013, the Company entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park"). The Lincoln Park equity facility allows the Company to require Lincoln Park to purchase up to 7,500 shares ("Regular Purchase") of the Company's common stock every two business days, up to an aggregate of $10.6 million over approximately a 36-month period depending on certain conditions, including the quoted market price of the Company's common stock on such date. The purchase price for the Regular Purchase shall be equal to the lesser of (i) the lowest sale price of the common shares during the purchase date, or (ii) the average of the three lowest closing sale prices of common shares during the twelve business days prior to the purchase date.</sngx:CommonStockPurchaseAgreementDescription>
<sngx:CommonStockPurchaseAgreementDescription contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">The Company entered into a common stock purchase agreement with Lincoln Park. The Lincoln Park equity facility allows the Company to require Lincoln Park to purchase up to 10,000 shares ("Regular Purchase") of the Company's common stock every two business days, up to an aggregate of $12.0 million over approximately a 36-month period with such amounts increasing as the quoted stock price increases. The Regular Purchase may be increased up to 15,000 shares of common stock if the closing price of the common shares is not below $10.00, up to 20,000 shares of common stock if the closing price of the common shares is not below $15.00 and up to 25,000 shares of common stock if the closing price of the common shares is not below $20.00. The purchase price for the Regular Purchase shall be equal to the lesser of (i) the lowest sale price of the common shares during the purchase date, or (ii) the average of the three lowest closing sale prices of the common shares during the twelve business days prior to the purchase date. Each Regular Purchase shall not exceed $750,000. Furthermore, for each purchase by Lincoln Park, additional commitment shares in commensurate amounts up to a total of 50,000 shares will be issued based upon the relative proportion of the aggregate amount of $12.0 million. In addition to the Regular Purchase and provided that the closing price of the common shares is not below $7.50 on the purchase date, the Company in its sole discretion may direct Lincoln Park on each purchase date to purchase on the next stock trading day (Accelerated Purchase Date") additional shares of Company stock up to the lesser of (i) three times the number of shares purchased following a Regular Purchase or (ii) 30% of the trading volume of shares traded on the Accelerated Purchase Date at a price equal to the lesser of the closing sale price on the Accelerated Purchase Date or 95% of the Accelerated Purchase Date's volume weighted average price.</sngx:CommonStockPurchaseAgreementDescription>
<sngx:MaximumCommitmentSharesUnderAgreementConsistOfCommitmentFee contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="shares" decimals="INF">10000</sngx:MaximumCommitmentSharesUnderAgreementConsistOfCommitmentFee>
<sngx:MaximumCommitmentSharesUnderAgreementConsistOfCommitmentFee contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">10000</sngx:MaximumCommitmentSharesUnderAgreementConsistOfCommitmentFee>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">81000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<sngx:MaximumAdditionalCommitmentSharesUponRelativeProportionOfPurchasesCompared contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="shares" decimals="INF">12207</sngx:MaximumAdditionalCommitmentSharesUponRelativeProportionOfPurchasesCompared>
<sngx:ProceedFromCommonStockAgreementGross contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="USD" decimals="-5">10000000</sngx:ProceedFromCommonStockAgreementGross>
<sngx:DescriptionOfPurchaseAgreement contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember">In addition to the Regular Purchase and provided that the closing price of the common shares is not below $15.00 on the purchase date, the Company in its sole discretion may direct Lincoln Park on each purchase date to purchase on the next stock trading day (''Accelerate Purchase Date'') additional shares of Company stock up to the lesser of (i) two times the number of shares purchased following a Regular Purchase or (ii) 30% of the trading volume of shares traded on the Accelerated Purchase Date as a price equal to the lesser of the closing sale price on the Accelerated Purchase Date or 95% of the Accelerated Purchase Date's volume weighted average price.</sngx:DescriptionOfPurchaseAgreement>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">22500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">82500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<sngx:IssuanceOfCommitmentShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">575</sngx:IssuanceOfCommitmentShares>
<sngx:IssuanceOfCommitmentShares contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1635</sngx:IssuanceOfCommitmentShares>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">470475</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">1339177</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<sngx:EquityLinePurchaseAgreementsDescription contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EquityUnitPurchaseAgreementsMember">Company issued to each of the Investors a promissory note having a principal amount equal to 3% of the total amount committed by such Investor.</sngx:EquityLinePurchaseAgreementsDescription>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_30_Sep_2007T00_00_00_TO_30_Sep_2007T00_00_00_AwardTypeAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2010T00_00_00_TO_31_Dec_2010T00_00_00_AwardTypeAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EquityIncentivePlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMember" unitRef="shares" decimals="INF">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">2523000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PlanNameAxis_EquityIncentivePlanMember" unitRef="shares" decimals="INF">252300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMember" unitRef="shares" decimals="INF">47700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_EmployeesMember" unitRef="shares" decimals="INF">2900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="shares" decimals="INF">9934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">815653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">205151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">726950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">248828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">492612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">276861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">16406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">29189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">16.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">7.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">6.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">5.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">31.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">31.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="USD_per_Share" decimals="1">3.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="USD_per_Share" decimals="2">22.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="USD_per_Share" decimals="2">46.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="USD_per_Share" decimals="2">5.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="USD_per_Share" decimals="2">14.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="USD_per_Share" decimals="1">22.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="USD_per_Share" decimals="2">41.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="USD_per_Share" decimals="2">94.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="USD_per_Share" decimals="2">5.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="USD_per_Share" decimals="2">20.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">P7Y3M11D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember">P2Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember">P8Y11D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember">P5Y4M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember">P3Y2M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember">P2Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">276861</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">492612</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="shares" decimals="INF">217084</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="shares" decimals="INF">17477</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="shares" decimals="INF">42300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="shares" decimals="INF">381180</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="shares" decimals="INF">111432</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">208220</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">492612</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOneMember" unitRef="shares" decimals="INF">148443</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeTwoMember" unitRef="shares" decimals="INF">17477</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeThreeMember" unitRef="shares" decimals="INF">42300</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFiveMember" unitRef="shares" decimals="INF">381180</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeFourMember" unitRef="shares" decimals="INF">111432</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">147027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">59695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">34.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">55.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">23.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P7Y3M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">256347</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">47241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">18181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">257369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">21.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">773197</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:Deposits contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1000000</us-gaap:Deposits>
<us-gaap:Deposits contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1000000</us-gaap:Deposits>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">257000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">157000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">56000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">16667</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">39333</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">251000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">151000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">251000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">151000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">152000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">52000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">152000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">52000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">860000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">500000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">360000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">659000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="0">416667</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="USD" decimals="0">242333</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<sngx:NumberOfCommonSharesTransferredToThirdParty contextRef="Context_Custom_01_Feb_2007T00_00_00_TO_28_Feb_2007T00_00_00_LeaseArrangementTypeAxis_DoctorSchaberMember" unitRef="shares" decimals="INF">5000</sngx:NumberOfCommonSharesTransferredToThirdParty>
<us-gaap:CommitmentsFairValueDisclosure contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">500000</us-gaap:CommitmentsFairValueDisclosure>
<us-gaap:CommitmentsFairValueDisclosure contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">416667</us-gaap:CommitmentsFairValueDisclosure>
<sngx:PaymentForCommitmentMilestones contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_03_Sep_2014T00_00_00" unitRef="USD" decimals="-6">10000000</sngx:PaymentForCommitmentMilestones>
<sngx:PaymentForCommitmentMilestones contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="-5">7900000</sngx:PaymentForCommitmentMilestones>
<sngx:PaymentForCommitmentMilestones contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="-5">7900000</sngx:PaymentForCommitmentMilestones>
<sngx:PercentageForRoyalties contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="2">0.06</sngx:PercentageForRoyalties>
<sngx:PercentageForRoyalties contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="2">0.06</sngx:PercentageForRoyalties>
<sngx:MonthlyRentAmountBeforeIncrement contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">12300</sngx:MonthlyRentAmountBeforeIncrement>
<sngx:MonthlyRentAmountBeforeIncrementPerSquareFoot contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="2">20.85</sngx:MonthlyRentAmountBeforeIncrementPerSquareFoot>
<sngx:MonthlyRentIncrease contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">12375</sngx:MonthlyRentIncrease>
<sngx:MonthlyRentIncreasesPerSquareFeet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="2">20.95</sngx:MonthlyRentIncreasesPerSquareFeet>
<sngx:MonthlyRentAmountAfterIncrement contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">12460</sngx:MonthlyRentAmountAfterIncrement>
<sngx:MonthlyRentAmountAfterIncrementPerSquareFoot contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="2">21.13</sngx:MonthlyRentAmountAfterIncrementPerSquareFoot>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">94400</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">142935</us-gaap:OperatingLeasesRentExpenseNet>
<sngx:NumberOfMonthsAfterthatRentIncreases contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">P12M</sngx:NumberOfMonthsAfterthatRentIncreases>
<sngx:NumberOfRemainingMonthsForWhichIncreasedRentPaid contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">P12M</sngx:NumberOfRemainingMonthsForWhichIncreasedRentPaid>
<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_03_Sep_2014T00_00_00" unitRef="USD" decimals="0">275000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_03_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">184912</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
<us-gaap:LeaseExpirationDate1 contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">2018-05-31</us-gaap:LeaseExpirationDate1>
<sngx:PercentageOfOwnershipOutstandingStock contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_03_Sep_2014T00_00_00" unitRef="pure" decimals="1">19.9</sngx:PercentageOfOwnershipOutstandingStock>
<sngx:SharesIssuedInConnectionWithAcquisitionOfInProcessResearchAndDevelopment contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_03_Sep_2014T00_00_00" unitRef="USD" decimals="0">3750000</sngx:SharesIssuedInConnectionWithAcquisitionOfInProcessResearchAndDevelopment>
<sngx:PurchaseAgreementRemainingTerm contextRef="Context_Custom_21_Mar_2016T00_00_00_TO_22_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember">P36M</sngx:PurchaseAgreementRemainingTerm>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_22_Mar_2016T00_00_00_TO_22_Mar_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_LincolnParkCapitaLfundLlcMember" unitRef="pure" decimals="4">0.0499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:StockholdersEquityReverseStockSplit contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_11_Nov_2016T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">The exercise price per share of the common stock under those warrants (after giving effect to the one-for-ten reverse stock split effective October 7, 2016) was reduced from $5.10 per share to $0.80 per share.</us-gaap:StockholdersEquityReverseStockSplit>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1510544</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1075835</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1343876</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">206881</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<sngx:ProceedsFromIssuanceOfCommonStockToSciclone contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<sngx:ProceedsFromIssuanceOfCommonStockToSciclone contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">3000000</sngx:ProceedsFromIssuanceOfCommonStockToSciclone>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Reclassification of Prior Year Presentation&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">Limits the use of NOLs to the extent there has been an ownership change of more than 50 percentage points.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
<sngx:WarrantsToPurchaseSharesExchangeCashlessExerciseBasis contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">42444</sngx:WarrantsToPurchaseSharesExchangeCashlessExerciseBasis>
<sngx:IncreaseDecreaseInWarrantLiability contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">430000</sngx:IncreaseDecreaseInWarrantLiability>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Item_1" xlink:label="lab_Item_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_1" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_3" xlink:label="lab_Item_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_3" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_4" xlink:label="lab_Item_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_4" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_5" xlink:label="lab_Item_5"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_5" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_6" xlink:label="lab_Item_6"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_6" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_7" xlink:label="lab_Item_7"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_7" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_8" xlink:label="lab_Item_8"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_8" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_9" xlink:label="lab_Item_9"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_9" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_10" xlink:label="lab_Item_10"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_10" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_11" xlink:label="lab_Item_11"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_11" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_12" xlink:label="lab_Item_12"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_12" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_13" xlink:label="lab_Item_13"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_13" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_14" xlink:label="lab_Item_14"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_14" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_15" xlink:label="lab_Item_15"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_15" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_16" xlink:label="lab_Item_16"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_16" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_17" xlink:label="lab_Item_17"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_17" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_18" xlink:label="lab_Item_18"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_18" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_19" xlink:label="lab_Item_19"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_19" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_20" xlink:label="lab_Item_20"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_20" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_21" xlink:label="lab_Item_21"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_21" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_22" xlink:label="lab_Item_22"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_22" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_23" xlink:label="lab_Item_23"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_23" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_24" xlink:label="lab_Item_24"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_24" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_25" xlink:label="lab_Item_25"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_25" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_26" xlink:label="lab_Item_26"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_26" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_27" xlink:label="lab_Item_27"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_27" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_28" xlink:label="lab_Item_28"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_28" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_29" xlink:label="lab_Item_29"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_29" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_30" xlink:label="lab_Item_30"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_30" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_31" xlink:label="lab_Item_31"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_31" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_32" xlink:label="lab_Item_32"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_32" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_33" xlink:label="lab_Item_33"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_33" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_34" xlink:label="lab_Item_34"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_34" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_35" xlink:label="lab_Item_35"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_35" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_36" xlink:label="lab_Item_36"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_36" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_37" xlink:label="lab_Item_37"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_37" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_38" xlink:label="lab_Item_38"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_38" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_39" xlink:label="lab_Item_39"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_39" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_40" xlink:label="lab_Item_40"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_40" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_41" xlink:label="lab_Item_41"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_41" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_42" xlink:label="lab_Item_42"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_42" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_43" xlink:label="lab_Item_43"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_43" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_44" xlink:label="lab_Item_44"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_44" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_45" xlink:label="lab_Item_45"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_45" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_46" xlink:label="lab_Item_46"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_46" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_47" xlink:label="lab_Item_47"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_47" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_48" xlink:label="lab_Item_48"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_48" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_49" xlink:label="lab_Item_49"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_49" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_50" xlink:label="lab_Item_50"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_50" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_51" xlink:label="lab_Item_51"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_51" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_52" xlink:label="lab_Item_52"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_52" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_53" xlink:label="lab_Item_53"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_53" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_54" xlink:label="lab_Item_54"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_54" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_55" xlink:label="lab_Item_55"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_55" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_56" xlink:label="lab_Item_56"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_56" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_57" xlink:label="lab_Item_57"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_57" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_58" xlink:label="lab_Item_58"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_58" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_59" xlink:label="lab_Item_59"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_59" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_60" xlink:label="lab_Item_60"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_60" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_61" xlink:label="lab_Item_61"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_61" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_62" xlink:label="lab_Item_62"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_62" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_63" xlink:label="lab_Item_63"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_63" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_64" xlink:label="lab_Item_64"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_64" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_65" xlink:label="lab_Item_65"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_65" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_66" xlink:label="lab_Item_66"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_66" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_67" xlink:label="lab_Item_67"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_67" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_68" xlink:label="lab_Item_68"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_68" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_69" xlink:label="lab_Item_69"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_69" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_70" xlink:label="lab_Item_70"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_70" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_71" xlink:label="lab_Item_71"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_71" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_72" xlink:label="lab_Item_72"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_72" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_73" xlink:label="lab_Item_73"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_73" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_74" xlink:label="lab_Item_74"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_74" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_75" xlink:label="lab_Item_75"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_75" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_76" xlink:label="lab_Item_76"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_76" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_77" xlink:label="lab_Item_77"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_77" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_78" xlink:label="lab_Item_78"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_78" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_79" xlink:label="lab_Item_79"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_79" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_80" xlink:label="lab_Item_80"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_80" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_81" xlink:label="lab_Item_81"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_81" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_82" xlink:label="lab_Item_82"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_82" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_83" xlink:label="lab_Item_83"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_83" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_84" xlink:label="lab_Item_84"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_84" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_85" xlink:label="lab_Item_85"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_85" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_86" xlink:label="lab_Item_86"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_86" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_87" xlink:label="lab_Item_87"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_87" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_88" xlink:label="lab_Item_88"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_88" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_89" xlink:label="lab_Item_89"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_89" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_90" xlink:label="lab_Item_90"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_90" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_91" xlink:label="lab_Item_91"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_91" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_92" xlink:label="lab_Item_92"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_92" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_93" xlink:label="lab_Item_93"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_93" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_94" xlink:label="lab_Item_94"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_94" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_95" xlink:label="lab_Item_95"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_95" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_96" xlink:label="lab_Item_96"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_96" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_97" xlink:label="lab_Item_97"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_97" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_98" xlink:label="lab_Item_98"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_98" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_99" xlink:label="lab_Item_99"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_99" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_100" xlink:label="lab_Item_100"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_100" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_101" xlink:label="lab_Item_101"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_101" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_102" xlink:label="lab_Item_102"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_102" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_103" xlink:label="lab_Item_103"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_103" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_104" xlink:label="lab_Item_104"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_104" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_105" xlink:label="lab_Item_105"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_105" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_106" xlink:label="lab_Item_106"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_106" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_107" xlink:label="lab_Item_107"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_107" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_108" xlink:label="lab_Item_108"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_108" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_109" xlink:label="lab_Item_109"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_109" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_110" xlink:label="lab_Item_110"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_110" xlink:to="Footnote_2" order="1.0"/>
<link:footnote xlink:type="resource" xlink:label="Footnote_2" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Adjusted to reflect the reverse stock split of one-for-ten effective October 7, 2016.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>


